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ABSTRACT 
Cervical cancer is a gynaecological malignant disorder and is a common cause of death in 
women of the sub-Saharan Africa, striking nearly half a million of females each year worldwide. 
Cervical cancer is due to the persistence infection of human papillomavirus (HPV), a formidable 
virus that targets the cervix and is present in most cancers of the cervix. In South Africa, plants 
used to treat cancer are rare and there is a need for screening further plant extracts in order to 
identify potentially new anti-cancer drug discovery leads.  
The purpose of this study was to screen Tulbaghia violacea (TV) and Agave palmeri (AG) for 
anti-cancer therapy in the cervical cancer cell lines HeLa and ME-180 and in the fibroblast cell 
line KMST-6. Staurosporine (ST) was used as a positive control. AG and TV crude plant extracts 
were screened for apoptosis induction, followed by elucidation of the role of Bax, Bcl-2, p53, 
Rb, RBBP and Mdm2 genes in cervical cancer. Plant extracts of TV and AG were time (24 
hours) and dose (50, 100, 150 µg/ml) dependently screened against cervical cancer cell lines 
HeLa, ME-180 and in KMST-6 for anti-cancer activity using the thiazolyl blue test (MTT) assay. 
With an IC50 ~ 150 µg/ml, T. violacea extract exhibited significant cytotoxicity on both HeLa 
and ME-180 cancer cell lines, whilst A. palmeri was cytotoxic to ME-180 cells and 25nM ST as 
a positive control had a cytoxicity effect on all cell lines including the KMST-6, yet TV and AG 
had no cytotoxic effect on KMST-6.  
The annexin-V/FITC detection assay was performed to evaluate the occurrence of apoptosis. 
Crude extracts of TV and AG together with ST induced significant apoptosis of HeLa, ME-180 
and KMST-6 cells. The crude extracts were further analysed for DNA fragmentation, protein 
expression and gene expression by Western Blot and RT-PCR respectively, to investigate 
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whether these extracts have an effect on the on the expression of Bax, Bcl-2, p53, Rb, RBBP6, 
Mdm2 and the relationship between p53 and RBBP6. Morphological and biochemical changes 
were seen in this study. A further mixed response by several genes was observed following 
treatment with the two plant extracts, where RBBP6 was seen to be spliced in cancer cells while 
Bax was induced and Bcl-2 was inhibited, but the levels of p53 remained the same. Preliminary, 
the extracts of TV and AG induce cell death by down-regulating Bcl-2 and Mdm2. Quantitative 
RT-PCR showed that when p53 was silenced RBBP6 was up-regulated and vice versa. From 
these results it was deduced that RBBP6 gene interacts with p53 during cervical cancer 
development. 
The anti-proliferative activity together with the characterization of p53, RBBP6 and Mdm2 and 
concentrations of these plant extract could be manipulated as diagnostic markers and potential 
therapeutic targets for cancer treatment; however, further studies on these plant extracts need to 
be performed to validate results obtained in this study. 
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CHAPTER 1 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1. Introduction 
This chapter provides a very brief introduction and literature review on the screening of 
traditional medicine for RBBP6 anti-cancer therapy in cervical cancer. There is no significant 
amount of literature available regarding the treatment of cervical cancer using traditional 
medicine, although there is literature available regarding cervical cancer and its screening and 
treatment with some traditional medicine in other countries but not in the South Africa 
perspective. This chapter will describe the epidemiology and natural history of cancer of the 
cervix and finally describe the use of traditional medicine in treating cervical cancer and 
other types of cancer. In a surge of combating and dealing with such a disease in the 
developing country like South Africa by using the natural resources such as plants as most 
people still consult traditional healers when sick.  
1.2. Cervical cancer 
1.2.1. Statistics 
Cervical cancer is a gynaecological malignant disorder and is the most common cause of 
cancer death in women of the Sub-Saharan Africa, Melanesia, South Central and South East 
Asia, the Caribbean and Latin America (Parkin et al, 1999; Hougardy et al, 2005; Danny, 
2006). In 2002, it was globally estimated that 493 000 new cases were diagnosed with 
274 000 women dead within the year (Danny, 2006). Most cases (83%) were reported in 
developing countries where cervical cancer accounted for 15% of all cancers, with a lifetime 
risk of 3% when compared to 3.6%- 4.4% in developed countries, with a lifetime risk of 1.1% 
and low incidence rate (age-standardized rate) which is less than 14 per 100 000 (Parkin et al, 
1999).  
According to the Cancer Registry of South Africa, in 1986 the total number of cancer cases 
reported was 16 559, of which 2897 (17.4%) were new cases of histologically confirmed 
cervical cancer. Whereas in 1992 about 25 143 cases of cancer were reported and cervical 
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cancer cases remained at the same proportion of 17.8% when compared to 1989. An average 
of 3387 new cases of cancer of the cervix were then reported each year in 1993-1995 and the 
age-specific incidence rate (ASIR) of cervical cancer was 22 per 100 000, 27 per 100 000 for 
black women in disadvantaged communities. The lifetime risk of developing cervical cancer 
is 1 in 34 in black women and 1 in 93 in white women of Southern Africa (van Schalkwyk et 
al, 2002; Walker et al, 2002). Possibly the lifetime risk is high in black women due to limited 
access to healthcare and these women normally present the case when it‟s too late.  To date, 
according to the World Health Organization (WHO, 2010) a South African population with 
16.84 million women ages 15 and above are at high risk of developing cervical cancer with 
5743 diagnosed and 3027 dying from cervical cancer. It is the most common cancer to affect 
black women, accounting for about 25% of cancer deaths and with 13.3% of South African 
females living with human immunodeficiency virus infection (HIV)/ acquired 
immunodeficiency syndrome (AIDS) because they are more susceptible to opportunistic 
diseases such as cervical cancer and have increased risk of contracting HPV (Kirsten, 2009). 
Cervical cancer is a third leading cause of death among women in Southern Africa with an 
overall age standardized incidence rate of 30 per 100 000 per year (Francis et al, 2010). 
Invasive cervical cancers are attributed to Human Papillomavirus (HPV) 16 and 18 according 
to WHO and the recent study indicated that worldwide HPV prevalence in cervical carcinoma 
is 99.8% (Schneider, 2004; Botha et al, 2010). 
1.2.2. Epidemiology  
The cause of cervical cancer is mainly due to the persistent infection of human 
papillomavirus which has more than 100 genotypes with varying virulence (i.e. HPV 16, 18, 
31, and 45) with HPV 16 accounting for more than 50% of cervical cancers, HPV 18 with 
10% followed by subtype 31 and 45 in most countries (Parkin et al, 1999; Hougardy et al, 
2005). Other co-factors of cervical cancer include multiple sex partners related to early onset 
of sexual activity which is thought to be associated with high risk because, during puberty, 
cervical tissue undergoes a variety of changes that may make the area more vulnerable to 
damage. Recurring sexually transmitted disease, smoking, oral contraceptive, family history, 
and molecular genetic factors such as loss of function in the tumour suppressor gene p53 to 
name but few factor that contribute to development of cervical cancer (Parkin et al, 1999; Lu, 
2004; Hougardy et al, 2005). 
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It is from the precursor lesions known as cervical dysplasia or cervical intraepithelial 
neoplasia (CIN) that, cervical cancer develops and can be classified as a mild (CIN I), 
moderate (CIN II) or severe (CIN III) or carcinoma-in-situ in terms of regression (Fletcher, 
1993, Soliman et al, 2004). The human papilloma virus consists of a double stranded circular 
DNA genome of 8 kilobases (kb), a non-enveloped virion and an icosahedral capsid which 
can infect mucosae and cutaneous surfaces together with epithelial cells thereby replicating 
episomally utilizing two of its virus- encoded proteins, E1 and E2 and causing warts and 
epithelial tumours (Chakrabarti and Krishna, 2003; Soliman et al, 2004; Hougardy et al, 
2005). It is rare for HPV to integrate into its host DNA but when it does integrate, it does so 
in a monoclonal fashion, which results in the loss of expression of the E2 protein. E2 
suppresses the expression of E6 and E7. Its loss results in the E6 and E7 overexpression 
(Finzer et al, 2002; Hougardy et al, 2005). The repression of both E6 and E7 in the study by 
Morrison et al, (2011) was previously shown to result in activation of their respective tumor 
suppressor targets, tumour protein (p53) and retinoblastoma protein (pRb), and subsequent 
senescence induction in cervical cancer cells. The E6 and E7 protein of oncogenenic HPV 
subtypes are co-expressed and facilitate degradation of cellular proteins that regulate the cell 
cycle and apoptosis and their oncogenes are essential in initiation and maintaining cervical 
cancer in high risk HPV (Morrison et al, 2011). The ability of viral DNA to integrate into the 
host is selective advantage towards progression of the HPV, because E6/E7 will continuously 
be expressed without losing the viral templates due to extrachromosomal segregation or 
encapsidation (Finzer et al, 2002). This will lead to the generation of virus-cell-fusion 
transcripts, whereby the own poly-A signal is lost and these E6/E7 mRNA are highly stable. 
This will, in turn, raise the amount of viral oncogenes resulting in the effect of cellular 
signalling or/and particular cellular transcription factors both at transcriptional and 
translational levels, whose function favour host cell transformation (Slebos et al, 1994; Finzer 
et al, 2002). Thus, E6 and E7 proteins of „high risk type‟ of HPV have been shown to be 
essential for cellular transformation via in vitro and in vivo studies (Chakrabarti and Krishna, 
2003). 
 
The E6 protein inactivates the p53 pathway while the E7 protein inactivates the 
retinoblastoma (Rb) pathway, both of which are essential in initiating and maintaining the 
proliferative state of cervical-cancer cells and thus an increased likelihood of malignant 
transformation (Soliman et al, 2004; Hougardy et al, 2005; Koushik et al, 2005). Together E6 
and E7 regions of the viral genome are also vital for maintaining the malignant phenotype 
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(Hamada et al, 1996). The HPV E6 has an ability to form a complex with and inactivate p53 
thereby stimulating p53 degradation through a selective [(E6-AP) ubiquitin ligase] ubiquitin-
dependent proteolytic pathway where the proteasome detects the proteins that have been 
targeted for degradation because ubiquitin peptides are attached to them (Figure 1.1) 
(Soliman et al, 2004; Hougardy et al, 2005). High oncogenic risk types of HPV (i.e. 16 and 
18) E6 proteins have a high affinity for p53 when compared to low-oncogenic risk types such 
as HPV 6 and 11. HPV 16 E7 interacts with various proteins, most of which are vital 
regulators of cell growth, these include retinoblastoma tumour suppresser family protein (Rb, 
p10, p130, histone deacetylases (HDAC), AP-1 transcription factors, TATA box binding 
protein (TBP), cyclins, cyclin-dependent kinases (cdks) and cdk inhibitors, M2 pryruvate 
kinase (M2-PK) which allows this protein to deregulate the cell cycle and increased cell 
proliferation, immortalization and finally transformation (Chakrabarti and Krishna, 2003). 
Alterations in the p53 gene, including deletion, insertion and point mutation are the most 
frequent genetic events in many different carcinomas, such as in colon, breast and lung 
(Bartek et al, 1990; Rodrigues et al, 1990; Takahashi, 1992).  
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Together E6 and E7 vastly contribute to carcinogenesis by suppressing apoptosis through 
targeting the host tumour suppressor gene products p53 and pRB together with senescence 
and by stimulating cellular proliferation and acceralating proteasomal degradation and 
inactivation (Figure 1.1) contributing to cellular immortalisation and transformation 
(Hougardy et al, 2005).  
1.2.3. Apoptosis and other cell death pathways 
Cell death occurs by various morphologically and biochemically distinct pathways which 
include apoptosis, necrosis, and autophagy. Apoptosis plays a vital role in embryogenesis and 
maintains homeostasis in multicellular organisms and is described as programmed cell death, 
a conserved mechanism directed by genes to eliminate damaged cells. (Taraphdar et al, 2001; 
Ghobrial et al, 2005; Sundquist et al, 2006; de Bruin and Medema, 2008). Apoptosis is 
induced by many stimuli, including growth factor withdrawal, ultraviolet or gamma radiation, 
chemotherapeutic agents, immunotherapy, or activation of death receptors (intracellular stress 
and extracellular ligand signals) (Hougardy et al, 2005; de Bruin and Medema, 2008). It is 
characterized by a series of distinct morphological and biochemical changes which include 
condensation, fragmentation of the nuclear chromatin, compaction of the cytoplasmic 
organelles with cell shrinkage and loss of positional organization of organelles in the 
cytoplasm, dilation of the endoplasmic reticulum, a decrease in cell volume and alteration to 
the plasma membrane resulting in the recognition and phagocytosis of the apoptotic cells 
(Lee et al, 2009; Taraphdar et al, 2001). Although apoptosis refers to a purely morphological 
change, biochemical events accompany these morphological changes and these events occur 
during the intrinsic and extrinsic pathway (Sundquist et al, 2006).  
 
The intrinsic and extrinsic signaling pathways initiate apoptosis. The intrinsic pathway which 
is due to intracellular stress signals, such as growth factor withdrawal, DNA damage, 
oxidative stress or oncogene activation. Which upon signal response lead to permeabilization 
of the mitochondrial outer membrane and is regulated by pro- and anti-apoptotic members of 
the Bcl-2 family in which members are either death antagonists or death agonists either 
repressing apoptosis. In turn, blocking the release of cytochrome-c or acting as a promoter of 
apoptosis by releasing cytochrome-c from the mitochondria (Ghobrial et al, 2005; De Bruin 
and Medema, 2008). In normal uterine cervix tissue cell proliferation and apoptosis is 
balanced, the imbalance of proliferation together with apoptosis may lead to squamous cell 
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carcinoma because these processes remain crucial for normal development and maintenance 
of tissue homoeostasis by eliminating damaged, virally infected, or otherwise harmful cells 
(Hougardy et al, 2005). Finzer et al, 2002 defines apoptosis due to viral infection (HPV) as a 
genetically determined programme where replicating or persisting viruses that are not yet 
packaged into mature viral capsid are cleaved. This process is mediated by activation of 
initiator and effector proteases called caspases which function to cleave specific death 
substrates, resulting in cellular disassembly (Lowe and Lin, 2000; Dlamini et al, 2004; 
Hougardy et al, 2005). This is very much dependent on the balance between the anti-
apoptotic protein Bcl-2 and the pro-apoptotic Bax than on Bcl-2 quantity alone according to 
the rheostat model that determines whether a cell will live or die in response to an apoptotic 
stimulus (Nickells, 2010). Bax therefore be activated to initiate mitochondrial dysfunction 
that is critical during the intrinsic apoptotic pathway. These proteins also undergo post- 
transcriptional modification, desphosphorylation and cleavage, which result to their 
mitochondrial activation and translocation leading to apoptosis (Scorrano and Korsmeyer, 
2003).  
 
Once the apoptotic stimuli is sent, the outer mitochondrial membrane becomes permeable 
and this leads to the release of cytochrome-c from the membrane space and the second 
mitochondrial-derived activator of caspase in the cytosol where cytochrome-c interacts with 
Apaf-1, leading to the activation of caspase-9 pro-enzyme (Ghobrial et al, 2005; Kang and 
Reynolds, 2009). This occurs in a cascade manner where caspase-9 activates caspase-3, 
which activates the rest of the caspases and this result into apoptosis (Dlamini et al, 2004). In 
a nutshell, cytochrome c will then bind to the protein apoptosis-protease-activating-factor 1 
(Apaf-1) forming a complex called the apoptosome since it is bound to dATP as a cofactor 
and it contains cytochrome c, Apaf-1 and initiator caspase 9 which is auto-induced within 
this complex (Purring-Koch and McLendon 2000; De Bruin and Medema, 2008). Active 
caspase-9 cleaves and activates other executioner caspases thus turning on a protease cascade 
which will eventually lead to cleavage of caspase-3 causing apoptosis (Li et al. 1997).  
 
The extrinsic pathway on the other hand, involves cell surface death receptors together with 
inducers and suppressors, which will aid in determining whether the cell will undergo mitosis 
or apoptosis (Ghobrial et al, 2005; Hougardy et al, 2005). In most cancers, the ability of the 
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cells to either undergo mitosis or apoptosis is impaired causing uncontrolled cell 
proliferation, which leads to tumour formation.  The extrinsic apoptotic pathway commences 
with the activation of death receptors on the cell membrane, which belong to the tumour-
necrosis-factor-receptor super-family (Hougardy et al, 2005). The binding of specific tumour-
necrosis-factor-receptor ligand such as FASL or tumour-necrosis-factor-related apoptosis-
inducing ligand TRAIL, to the cognate receptors FAS and DR4 or DR5 respectively triggers 
apoptosis in this pathway (de Bruin and Medema, 2008). As a result of this activation an 
intracellular death-inducing signaling complex composed of trimerised receptor molecules, 
recruited FAS-associated death domain molecules and procaspase-8 molecules, causes 
activation of the caspase-8 intracellular apoptotic cascade leading to the cleavage of several 
substrates in the cytoplasm and nucleus and completion of the apoptotic process (Hougardy et 
al, 2005). Caspase-3 is also involved in this pathway as it is activated by caspase-8 directly or 
indirectly by cleaving BID (a death agonist protein from the Bcl-2 family). Cleaved or 
truncated BID translocates into the mitochondria whereby it triggers the apoptotic pathway 
(Dlamini et al, 2004; Hougardy et al, 2005; de Bruin and Madema, 2008). In both pathways, 
apoptotic biochemical events occur after activation of the effector caspases and this includes 
the phosphatidylserine exposure on the external surface of the plasma membrane, cleavage of 
poly (ADPribose) polymerase (PARP) and internucleosomal DNA fragmentation (Sundquist 
et al, 2006).  
 
The capability to interfere with these apoptotic pathways allows human papillomavirus 
oncoproteins to interfere with normal balance between proliferation and apoptosis in HPV-
infected cervical epithelial cells. The virus escapes detection by the immune system during 
progression to cervical cancer and strategically modulates the apoptotic response upon 
infection (Finzer et al, 2002; Hougardy et al, 2005). For example, escape from the host 
immune system can be favored, by the fact that HPV is able to down-regulate the major 
histocompatibility complex (MHC) class I expression and the loss of TAP-1 transporter 
protein expression together with the ability to present foreign antigens (i.e. E2 and E6) to 
cytotoxic T cells (CTL) (Cromme et al, 1994; Bartholomew et al, 1997; Bontkes et al, 1998; 
O‟Brien and Campo, 2003). If the viral infection persists, its oncoproteins degrade p53 and 
inactivate Rb tumour suppressor genes thus HPV proteins are vital for cervical 
carcinogenesis (Hamada et al, 1996). Thus, DNA viruses are strategically able to modulate 
apoptosis e.g. adenovirus-infected cells are able to overcome the antiviral host defense by 
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degrading the CD95-receptor and interfere with normal function of tumour suppressor genes 
(Finzer et al, 2002).    
1.2.4. Tumour suppressor genes (TSG) 
The tumour suppressor genes not only regulate the growth of cells but they function to inhibit 
tumour growth. When they are inactivated or altered by i.e. genetic and epigenetic mutations 
and their inhibitory function is lost thus causing cancer. When proteins encoded by these 
genes are no longer expressed, cell proliferation cannot be inhibited. There are various types 
of these genes; some are responsible for directing information to the cell so that it stops 
dividing (cell cycle arrest), others control DNA damage by repairing it whereas others are 
responsible for apoptosis a form of cell death (Ghobrial et al, 2005). Genes such as p53 and 
retinoblastoma (Rb) gene, to name but few, play a major role in cancer. 
1.2.4.1. p53 
Approximately about 70% of all human cancers carry p53 mutations, and recent studies 
suggest that many tumours that retain wild-type p53 are defective in either the ability to 
induce or the ability to respond to p53 (Oren, 1999; Bertram, 2001). The mechanism of 
inactivation or loss of wild type p53 in the development of cervical carcinoma is attributed to 
either mutation within the genome or the presence of a virally encoded p53 binding protein 
such as E6 thus causing carcinogenesis (Hougardy et al, 2005). The tumour suppressor gene, 
p53 encodes a 53kDa recessive loss-of-function protein (an oligomeric transcription factor), 
and, by binding to specific DNA target sequences, either activates or represses expression of 
a number of genes that regulate the cell cycle, differentiation, DNA repair and apoptosis 
(Classon and Harlow, 2002; Dlamini et al, 2004; Motadi et al, 2007). The function of the p53 
gene was confirmed through the study of germ-line mutations of p53 gene in families with 
Li-Fraumeni syndrome (LFS), in which affected individuals were predisposed to early-onset 
malignancies including breast carcinoma, sarcomas, and brain tumors (Frebourg et al, 1995). 
 
The mechanism of p53 activation in response to DNA damage is dependent on DNA protein 
kinase and other oncogenic proteins such as Myc, Ras, adenovirus E1A, and β-catenin (Oren, 
1999; Abd El All et al, 1999; Ryan et al, 2001). The p53 gene negatively regulates the cell 
cycle and requires „„loss of function‟ mutations for genomic instability, impaired cell cycle 
regulation and inhibition of apoptosis results into tumour formation whereas the activation 
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induces cell cycle arrest, initiates apoptosis and regulates cell senescence to defend the host 
cell against cancer (Soliman et al, 2004; Ghobrial et al, 2005). Thus, the pivotal role of p53 
is to maintain the genome‟s integrity either by inducing cell cycle arrest or apoptosis hence 
the nickname “guardian of the genome” (Oren, 1999; Bertram, 2001). Post mitosis, during 
the G1 phase of the cell cycle, p53 levels are normally low and protein levels are 
phosphorylated by the M phase cyclin-dependent kinase (CDK) pathway which includes a 
major gene target of p53, the CDK inhibitory protein, p21. This is a negative regulator 
growth factor that protects cells against apoptosis by invoking the cyclin-dependent kinase 
and caspase pathways (Motadi et al, 2007; Ryan et al, 2001).  
 
If p53 is activated this will result in an increased expression of p21 and the cell cycle will 
arrest at G1 and G2 phase. Apoptosis is regulated by the activation of down-stream targets 
that are directly involved in the control of apoptosis, where p53 binds to mouse double 
minute (Mdm2). In turn, p53 levels are regulated via a negative feedback loop in which p53 
stimulates the expression of mdm2 protein which in turn inhibits p53 by binding to its 
transcriptional domain, acting as an ubuquitin ligase, which promotes p53 degradation, by 
binding p53 and exporting it to the nucleus (Motadi et al, 2007). On the other hand, the 
binding of MDM2 to the amino-terminal transactivation domain of p53 directly inhibits the 
transcriptional activation and repression by p53 and this results into retinoblastoma protein 
(pRb) forming a trimeric complex with Mdm2 and p53, preventing p53 degradation. Thus, 
Rb may enhance p53-dependent cell death (Ryan et al, 2001).  
1.2.4.2. Retinoblastoma (Rb) 
Retinoblastoma (Rb) gene, encoding protein pRb was the first tumour suppressor gene to be 
cloned and was discovered to be mutated in human cancers, such as small-cell lung 
carcinoma and asteosarcoma (Classon and Harlow, 2002). Rb is a member of „pocket 
proteins‟, which include p107 and p130 with main sequence similarity in the domain that 
mediates interaction with many proteins including viral oncoproteins. The gene product, Rb 
is a target of oncoproteins that are expressed by DNA tumour viruses, i.e. adenovirus E1A, 
SV40 T antigen and the E7 protein of HPV although in cervical carcinomas that do not 
express the E7 protein, the activity of Rb is inactivated by somatic mutation in order to cause 
cancer (Classon and Harlow, 2002; Sherr and McCormick, 2002).  
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The cell is upheld at a checkpoint after DNA damage. This lasts until the damage is repaired 
and if this damage is irreversible, apoptosis is triggered (Ghobrial et al, 2005). Loss of 
function of Rb protein which regulates the G1/ S phase checkpoint by binding to E2F family 
transcription factor and inhibiting promoters of expression genes required for transition 
results in uncontrolled cell proliferation or cancer (Ahlander and Bosco, 2009; Poznic 2009). 
These findings suggest that Rb is a regulator of cell proliferation as this was shown through 
overexpression studies where Rb was overexpressed and the cells underwent arrest in the G1 
phase of the cell cycle, whereas cells deficient of Rb underwent an acceralated G1 transition 
implying the role of Rb as a cell proliferation inhibitor (Classon and Harlow, 2002). The 
ability of Rb to repress E2F- mediated transcription is controlled by the phosphorylation of 
Rb by the cyclin-dependent kinase (CDKs) such as CDK1 where the interaction between Rb 
and E2F is disrupted (Buchkovich et al, 1989). Rb is also implicated in playing a pivotal role 
in DNA replication, differentiation, and in apoptosis. Therefore, the decrease in 
differentiation potential with an increase in proliferation rate in Rb deficient cells, contribute 
to tumourigenesis. Rb deficiency is lethal at E1A. In knockout mice it was shown that after 
14 to 15 days of embryonic development they die (Sherr and McCormick, 2002). 
 
The roles of Rb and p53 are interconnected because both these tumour suppressor genes and 
their protein products play similar roles. Proteins p53 and Rb require specific protein-to-
protein interactions to mediate their respective functions and they interact with RBBP6, a 
retinoblastoma binding protein 6 (RBBP6) in vivo and in vitro (Li et al, 2007). This 
interaction concurrently promotes p53 degradation via a proteasome pathway enhancing the 
activity of Mdm2 gene (figure 1.2) (a p53 inhibitor with ubiquitin ligase activity) a key p53 
negative regulator thereby suppressing p53 binding to DNA (Soliman et al, 2004; Pugh et al, 
2006; Ntwasa, 2008). On the other hand RBBP6 may also block the binding of adenovirus 
E1A protein to Rb (Pugh et al, 2006). 
1.2.4.3. RBBP6 
RBBP6 is a 250kDA multi-domain splicing-associated protein which adopts a ubiquitin-like 
fold (N-terminal domain DWNN) as shown in figure 1.2, and has a conserved zinc finger like 
motif with an ability to localize itself into the chromosome during mitosis and to nuclear 
speckles, which are believed to be the main site of activity for pre-mRNA splicing and 
processing, during interphase. Over-expression leads to cell cycle arrest and apoptosis (Pugh 
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et al, 2006; Ntwasa, 2008). This tumour binding protein in its truncated form may also be 
referred to as a potential related protein (P2P-R) or p53-associated cellular protein (PACT) 
due to its ability to bind to p53 (Simon et al, 1997; Li et al. 2007). Such interactions interfere 
with ability of p53 and Rb to bind to damaged DNA and EF2 resulting into apoptosis 
inhibition and induced cell proliferation respectively (Chibi et al, 2010). RBBP6 negatively 
regulates pre-mRNA processing proteins by covalently modifying them with an ubiquitin-like 
moiety and localizing to chromosomes during the mitotic cell cycle and to nuclear speckles, 
active sites for pre-mRNA splicing and processing, during interphase (Pugh et al, 2006). This 
later led to the discovery that P2P-R is actually an alternatively spliced form of PACT which 
lacks the 34 amino acid exon (Faro, 2004). P2P-R protein levels are highly expressed during 
mitosis, and are phosphorylated by the mitotic cdc2 kinase. Over-expression results into 
mitotic arrest at prometaphase and mitotic apoptotic (Scott et al, 2005).  Over expression of 
the pro-apoptotic region discovered within the P2P-R in breast cancer cell lines (MCF-7) 
promoted camptothecin induced apoptosis because this region overlapped the region 
responsible for p53 and single stranded DNA binding (Faro, 2004).  
 
A more recent study by Li, et al, 2007 revealed a biological function of Pact, where knockout 
mice were generated and it was discovered that the disruption of PACT led to early 
embryonic lethality before embryonic day 7.5 accompanied by widespread apoptosis. To 
study the biological functions of Pact, PACT knockout mice were generated and found that 
disruption of PACT leads to early embryonic lethality before embryonic day 7.5 (E7.5) 
accompanied by widespread apoptosis together with p53 accumulation in vivo. Therefore, 
PACT was deduced to be involved in the negative regulation of p53 function through 
ubiquitin-dependent proteolysis by Mdm2 and implies a critical role for PACT in 
development and a considerable implication in tumourogenesis (Li et al, 2010). Therefore 
Mdm2 almost plays a similar role as RBBP6, in the sense that it functions as E3 ubiquitin 
ligase that is responsible for ubiquitination and degradation of p53 inactivating apoptosis and 
causing cell cycle arrest (Iwakuma and Lazano, 2004). In certain studies RBBP6 was shown 
to be upregulated in oesophageal cancer cells, and this high expression level went hand in 
hand with high rate of proliferation in these cells, thus cytotoxic T cells and antibodies 
specific against RBBP6 could successfully be utilized in immunotherapy against this cancer 
to allow the regression in mice xenograft models leading to decrease in tumour size (Pugh et 
al, 2006 and Muleya, 2010). 
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RBBP6, therefore, is involved cancer development due to the presence of RING finger 
domain in all homologues and the DWNN domain, which regulate pre-mRNA processing of 
proteins by covalently modifying them with an ubiquitin-like moiety. Similarly playing a role 
as an ubiquitin-like modifier thereby promoting cell proliferation because ubiquitination leads 
to targeted break-down (figure 1.2) (Pugh et al, 2006). The p53-binding domain is known to 
interact with p53, this resulting into a suppression of p53 binding to DNA. On the other hand, 
the Rb domain binds to Rb, blocking the binding of E2F transcription factors (Figure 1.2) 
(Pugh et al, 2006). Most cancers begin with the loss of function of some tumour suppressor 
genes followed by the accumulation of mutations in oncogenes and in tumour suppressor 
genes. The loss of function of p53, Rb including high expression of RBBP6 in some human 
tumours may alter the response to chemotherapeutic agents (Bertram, 2001). Restoring of p53 
function together with alteration the function of many other tumour suppressor genes make 
an attractive target for gene therapy. For example, in pre-clinical studies it has been shown 
that introducing a wild- type p53 into prostate and lung tumour cells with mutated p53 results 
in apoptosis and injection of p53 vectors into tumours of immune-suppressed nude mice 
results into inhibition of cell proliferation (Bertram, 2001).  
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Chemotherapeutic agents provide a cure to cancer and comprise a diverse group of 
compounds with different mechanisms of action. But their ultimate ability to induce 
apoptosis represents a unifying concept for the mechanism of chemoprevention and treatment 
(Taraphdar et al, 2001). For instance, prevention or treatment of cervical cancer for example, 
is categorized into three areas of primary, secondary, and tertiary. The primary strategy aims 
to reduce the incidence of disease by targeting the entire population without symptoms and 
diseases. In cervical cancer, this includes preventive vaccines and risk reduction. The 
secondary strategy involves early detection or screening in an aim to reduce prevalence of the 
cervical cancer by Papanicolau smear and HPV detection. The tertiary strategy involves 
reduction of recurrence or early detection of recurrence, which includes therapeutic vaccines 
(Sasieni, 2006; Sitas et al, 2008, Frazer, 2008). Cervical cancer treatment regimens depend 
on several factors including the type and stage of cancer, possible side effects and individual 
preference. Surgically the tumour or surrounding tissue can be removed during an operation 
if the cancer has not spread beyond the cervix. Methods like conization which remove 
microinvasive cervical cancer have been used; hysterectomy, radition and chemotherapy have 
been vastly used if the cancer has spread beyond the cervix (Chien et al, 2011).  It is therefore 
vital to investigate other chemoprevention strategies such as traditional medicine as a 
potential target for anti-cancer therapy. 
1.3. Traditional medicine in apoptotic induction 
More than 50% of all modern drugs in clinical use are derived from natural products, many of 
which have an ability to control cancer cells and even HIV/AIDS (Richter, 2003; Madhuri 
and Pandey, 2009). In the United States, 25% of the pharmaceutical prescriptions contain at 
least one plant-derived ingredient; therefore plants are a vital source of medicine (Samy and 
Gopalakrishnakone, 2007). There are about 69% of anti-cancer drugs, which were approved 
between the 1980‟s and 2002 and were evidently derived from natural products or developed 
on the knowledge gained from natural products (Newman and Cragg, 2007). In industrialized 
countries, medicinal herbs gradually lost importance during the course of chemistry‟s 
progression in the 20
th
 century but they are currently experiencing an impressive revival 
(Efferth et al, 2008). Various plant products are known to induce apoptosis in neoplastic cells 
but not in normal cells. Since apoptosis is pivotal mode of action for anti-tumour agents, such 
as ionizing radiation, alkylating agents [cisplatin and 1-3-bis (2-chloroethyl)-1 nitrosourea 
(BCNU)], topoisomerase inhibitor etiposide, cytokine tumour necrosis factor (TNF), taxol, 
and N-substituted such as metoclopramide and 3-chloroprocainamide are able to induce 
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apoptosis without affecting normal cells (Taraphdar et al, 2001). It is thus considered vital to 
screen apoptotic inducers from plants, either in the form of crude extracts or as components 
isolated from them. 
1.3.1. Plant extracts treating cancer and other diseases 
A number of scientific investigations have highlighted the importance of many plant families 
(i.e. Apocynaceae, Vitaceae, Nyssaceae, to name but few) used as medicinal plants that play 
a vital role in the development of new drugs where bioactive compounds such as viniblastine, 
vincristine which treat lymphocytic leukemia, small cell lung, cervical and breast cancer can 
be exported or imported in the current market (Fabricant and Farnsworth, 2001; Samy and 
Gopalakrishnakone, 2007; Efferth et al, 2008). Natural products such as Vinca alkaloids 
obtained from Catharanthus roseus G. Don, family Apocynaceae; the DNA topoisomerase I 
inhibitor camptothecin from Camptotheca acuminate Decne. (Nyssaceae) and Resveratrol, 
which is derived from Vitis vinifera belonging Vitaceae family, possess anti-inflammatory 
and anti-mutagenous activities that are potential cancer chemopreventive agents (Hutching et 
al, 1996; Neuwinger, 1996; Jang et al, 1997; Lin et al, 1999; Cragg and Newman, 2005).  
Plants are therefore utilized in producing novel or known structures as lead compounds for 
semisynthesis to produce patentable entities of higher activity and/or lower toxicity such as 
taxotere, galegine. Using these agents as pharmacological tools or the whole plant/part of it as 
herbal remedies (e.g. cranberry, Echinacea, feverfew, garlic, ginkgo bibola, St. John‟s wort, 
saw palmetto) is advantageous. Since majority of chemotherapeutants have been reported to 
severely affect normal host cells and plant “natural” are considered ineffective to normal cells 
(Fabricant and Farnsworth, 2001, Taraphdar et al, 2001).   
 
Experimentally and clinically, medicinal plants have been found to be effective against 
various types of cancers or tumours such as sarcoma, lymphoma, carcinoma and leukemia i.e. 
Saphora flavescens and S. subprostrata are effective in treating leukemia (and cervical cancer 
cells) and Indian Nothapodytes nimmoniana (Mappia foetida) is used to treat cervical cancer 
in Japan (Samy and Gopalakrishnakone, 2007; Madhuri and Pandey, 2009). Some of these 
plants possess immunomodulatory stimulating non-specific immunity together with specific 
immunity and antioxidant properties that may prevent and cure cancer and other diseases by 
protecting cells from highly reactive oxygen compound damage (Madhuri and Pandey, 2009). 
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Thus, much plant- derived products have been reported to exhibit strong anti-tumour activity 
against several rodent and human cancer cell lines.  
 
In the studies done on S. frutescens by Zhao et al. (2003) and Nile et al. (2003), plant extracts 
were able to induce apoptosis in cancer cells. Thus, this plant can be utilized to generate 
therapeutic drugs because it induces apoptosis as this is one approach in cancer therapy. In 
Japan, sho-saiko-to consisting of crude ingredients extracted from Bupleuri radix, Pinelliae 
tuber, Scutellariae radix, Zizyphi fructus, Ginseg radix, Glycyrrhizae, and Zingiberis rhizome 
has been reported to suppress proliferation of human HCC cell line and cholangiocarcinoma 
cells because ingredients such as glycyrrhizin and baicalein can interfere with the cell cycle at 
the G0G1 phase in vitro and with DNA synthesis. This herbal medicine was reported to have 
not affected normal PBL human cells when water-soluble ingredients of sho-saiko-to were 
used (Yano et al, 1994). On the other hand, Opuku et al. (2000) demonstrated that aqueous 
extracts form medicinal plants of Vitaceae in South Africa showed anti-proliferative activities 
of up to 97% inhibition in vitro against HepG2 cells. Ethanolic extracts of S. frutescens in the 
study by Stander et al, 2007 inhibited proliferation of about 50% of MCF-7 mammary 
adenocarcinoma cells over the period of 72 hours at a concentration of 1.5mg/ml.  
 
Southern African plants such as Tulbaghia (known as a wild garlic herb) species are known 
to treat various ailments such as fever, cold, asthma, tuberculosis, stomach-ache and even 
cancer of the esophagus (Van Wyk and Gericke, 2000). The sulfur-containing compounds 
found in this species were discovered to attribute to their characteristic smell and taste and 
other compounds are essential for antibacterial activity (Lyantagaye, 2011). Compounds 
2,4,5,7-tetrathiaoctane-2,2- dioxide and 2,4,5,7-tetrathiaoctane found on leaves of T. violacea 
were found to have antibacterial activity and their crude aqueous extracts have been shown to 
exhibit apoptosis inducing ability, and so potentially these extract can be used as anticancer 
agents (Burton, 1990; Lyantagaye and Rees, 2003; Davison et al, 2012). Derived compounds 
of T. violacea containing a methyl-%-D-glucopyranoside (MDG) moiety in their structure are 
postulated to interfere with the bioactivities of hexokinase, as well to induce reactive oxygen 
species, which cause cellular damage and result in apoptotic cell death in the study by 
Lyantagaye et al, 2005. The Agavaceae families of plants, such as Agave americana, have 
been reported to traditionally treat high blood pressure in Africa and their concentrated sap 
 16 
 
and extract have anti-bacterial activity and anti-inflammatory effect respectively (Anajwala et 
al, 2010). In the study by Anajwala et al, 2010 on the MCF-7 breast cancer cell line, it was 
reported that methanolic extract of A. americana show potent toxicity by MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide and SRB (sulforhodamine B) assay. 
Crude extracts on the other hand were discovered to possess two compounds that are similar 
to the neurotransmitter; acetylcholine and these compounds may be involved in cytotoxicity 
(Hackman et al, 2006).  
 
There has been some success in the use of traditional medicinal products approach to anti-
cancer drug discovery. Natural products like staurosporine (ST) isolated from Streptomyces 
stausporeus are known successfully induce cell cycle arrest or apoptosis at varying 
concentration in many types of cancers (Bernard et al, 2001). But little is known about 
Southern African plants used to treat cancer, thus screening various plant extracts to identify 
potentially new anti-cancer drugs is ideal. The molecular mechanisms underlying cancer 
progression and cell death has been intensively studied. Yet, facilities for diagnosis and 
treatment or even palliation of cancer in developing countries like South Africa are extremely 
limited and many people are dependent on traditional medicine because of their accessibility 
and affordability (Denny, 2006; Steenkamp, 2003; Fouche et al, 2008). It is therefore vital to 
screen traditional medicinal products together with RBBP6 for anti-cancer action in cervical 
cancer.  
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1.4. Objectives and Rationale  
 
The purpose of this study is to screen several South African traditional medicinal plants for 
anti-cancer therapy in cervical cancer. It is necessary to test whether there are any natural 
products that can be used in combination with several apoptosis inducing genes such as 
RBBP6 to act as anti-tumour agents. The understanding of the role of RBBP6 and apoptosis 
in the development of cervical cancer (especially HPV-induced cervical cancer) might lead to 
the development of new anti-cancer therapeutic drugs/vaccines that may guide tumour cells 
to apoptosis without being toxic to normal cells.  
 
 To treat human cervical carcinoma cells lines (HeLa and ME-180) and normal human 
fibroblasts (KMST-6) with different concentrations of traditional crude plant extract 
of Tulbaghia violacea and Agave palmeri and then evaluate the cytotoxic activity of 
these plant extracts by measuring cell viability. 
 
 To determine the mode of cell death induced by plant extracts of T. violacea and A. 
palmeri (whether apoptotic or necrotic) on HeLa, ME-180 and KMST-6 using flow 
cytometry. 
 
 To extract protein of untreated and treated HeLa, ME-180, and KMST-6 cell lines 
after treatment with plant extracts that induce cell death and assess protein expression 
of Bax, Bcl-2, p53, Rb, Mdm2 and RBBP6 by immunoblotting.   
 
 To elucidate the role of RBBP6 and p53 genes in cervical cancer. 
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CHAPTER 2 
MATERIALS AND METHODS 
2.1. Introduction 
In this current chapter procedures together with principals of each technique used in this 
study will be further discussed before elaborating on the protocol of each technique. 
Techniques used in this study include the following: Cell Cytototixity Assay (MTT Assay), 
Flow Cytometry (FITC Annexin V Apopotosis Detection kit I) using FACSDiva version 6.2, 
Polymerase Chain Reaction (PCR), RT-PCR and immunoblot analysis (western blot). 
Chemicals, supplies, recipes for solutions together with equipment used will be given 
appendix A and B.    
 
2.2. Materials 
2.2.1. Cell lines  
In this study, both non-tumourigenic and tumourigenic cell lines were used to characterize the 
role of various South Africa medicinal plants. These cell lines were purchased from the 
Health Science Research Resources Bank of the Japanese Collection of Research Bio-
resources (JCRB). They include the following: HeLa (carcinoma of cervix), ME180 (cervical 
carcinoma), and the non-tumourigenic immortalized human cell lines, KMST-6.  
Cell lines were cultured in 25cm² cell culture flasks and maintained in Eagle‟s minimum 
essential media (MEM with L-glutamine)/ Dulbecco's Modified Eagles Medium (DMEM) 
supplemented with 10 % Fetal Bovine Serum (FBS) and 1% Penicillin streptomycin 
(pen/strep) (Sigma Aldrich). Cell cultures were maintained at 37ºC in an incubator with 5% 
carbon dioxide (CO2) atmosphere. Cells were grown to 70-80% confluence as a monolayer, 
the medium was discarded and cells were washed with sterile Phosphate Buffered Saline 
(PBS). The cells were trypsinised using 2ml of trypsin/ethylenediaminetetra-acetic acid 
(EDTA) (Sigma Aldrich) and incubated at 37ºC to allow detachment. Medium was added to 
stop the trypsin reaction.  
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2.2.2. Plant material and extract preparation 
Agave palmeri and Tulbaghia violacea stem and leaves were collected from the arid highland 
region of South Africa (SA), in Limpopo.  Some of the plants material was obtained from 
Prof L.J. Mampuru from the University of Limpopo, Turfloop (School of Molecular and Life 
Science). Stems and leaves were dried in an oven. Using liquid nitrogen, the plant material 
was blended and the powder mixture was then weighed and mixed with distilled water 
(dsH2O). The suspension was filtered through Whatman® qualitative filter paper (Sigma 
Aldrich) overnight. The filtrate was then weighed and homogenized with Dimethyl sulfoxide 
(DMSO) to a required concentration of 40mg/ml. This was further be passed through the 
0.45μm and 0.22μm filters to obtain a purified stock solution that was further diluted with 
MEM and DMEM supplemented with 10% FBS and 1% pen/strep to make 50, 100, and 
150µg/ml (w/v) for the treatment of cell lines.  
 
2.3. Methods 
2.3.1. Cell Cytotoxicity Assay (MTT Assay)  
The MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide] is a colorimetric 
assay method used to measure cell cytotoxicity of potential medicinal agents such as A. 
palmeri and T. violacea plant extract because of their ability to stimulate and inhibit cell 
viability and growth. Cell proliferation (cell culture assay) together with viability (cell 
counting) can be measured by the capability of enzyme activity that reduces MTT in 
metabolically active cells (a pale yellow coloured substrate) to an insoluble formazan dye 
which is insoluble and gives a purple colour once solubilised for spectrophotometer 
measurement (Mossman, 1983). 
Ninety six well tissue culture plates were used to culture cells for the MTT assay. The 5 x 10
4
 
cells of HeLa, ME180, and KMST-1 in 90µl media were seeded into each well and incubated 
overnight at 37
o
C prior to treatment with varying concentrations of plant extract of A. palmeri 
and T. violacea (50, 100, 150µg/ml (w/v)). Other wells were left for a non-treatment control 
and a blank with only cells and media and the other well seeded with cells to be treated with 
25nM staurosporine (ST) a known apoptosis inducer (positive control). Cells were treated 
with plant extract and ST for 24 hours. Later, 10 µl of MTT (prepared to 5mg/ml PBS) 
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(Appendix A1) was added to each well except for the blank and the plates were further 
incubated for 4 hours. To dissolve the formazan crystals formed, 90 µl of DMSO was added 
and the optical density was measured using a spectrophotometer (Bio-Rad Microplate reader) 
with a reference of 570nm wavelength to obtain absorbance (Abs) values, which is a direct 
representation of viable cells.  
Cell viability was calculated as follows: 
                
[                                 ]
[                                    ]
     
 
2.3.2. Flow Cytometry (Annexin V- FITC Staining) 
This assay aids in measuring membrane alteration of an individual cell in a homogenous 
population in order to distinguishing live, apoptotic (early/ late) and necrotic cells (Rahman, 
2005). A number of cell surface changes occur during apoptosis i.e. phospholipid 
distribution, which is asymmetrical with the inner membrane containing anionic 
phospholipids such as phosphatidyl-serine plus an outer membrane with neutral phospholipid 
in normal cells. The amount of phosphatidylserine (PS) on the outer surface of the membrane 
increases in the apoptotic cell, exposing PS to the surrounding liquid (Lassota, 1992).  After 
the MTT assay, flow cytometry was used to analyse the cytotoxic effect of T. violacea, A. 
palmeri and staurosporine on HeLa, ME-180 and KMST-6 cell lines.  
 
To quantitatively determine the percentage of cells within the population that are undergoing 
apoptosis, the annexin V-FITC apoptosis detection kit from BD Biosciences was used. 
Annexin V (a calcium-dependent phospholipid-binding protein) conjugated to a 
flourochrome probe, flourescein isothiocyanate (FITC) is used in conjunction with propidium 
iodide staining solution for flow cytometric analyses of cells undergoing apoptosis or 
necrosis respectively (Hawley and Harley, 2005). This is because annexin V has a high 
affinity for PS exposed on surface of apoptotic cell and will not bind to living cells. Because 
2 flourochromes were used in this experiment and emission profiles are known to coincide in 
such cases, fluorescence compensations and gating procedures were set by having flask of 
cells of untreated cells and treated cells which were FITC annexin V only stained, PI stained 
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only, unstained, annexin V/PI stained to obtain control readings which eliminate results of 
unwanted particles e.g. debris (Rahman, 2005).  
About 1x10
5
 HeLa, ME180, and KMST-6 cells were incubated overnight at 37
o
C to 70% 
confluency in 25cm² cell culture flask (section 2.2.1) and treated with 150µg/ ml 
concentrations of natural plant extract of A. palmeri, T. violacea and 25nM staurosporine 
(positive control) for 24 hours because in these concentrations approximately 50% cell death 
was induced according to MTT assay studies. A negative control of untreated and singled 
stained annexin V/PI cells was also included to eliminate cell debris and quantify each dye 
with which a particular cell is labeled. After which, the cell population of interest was 
selected by creating a gate around the population of about 5000 cells of interest per run. Cells 
were then detached by trypsinization (Trypsin-EDTA) (section 2.2.1), 1ml cold PBS was 
added and cells were transferred into 1ml eppendorf tube, then centrifuged at 400 g for 
5minutes. The supernatant was discarded and the pellet was wash in cold PBS twice. After 
these washes the pellet was resuspended in 100µl 1X binding annexin V binding buffer at a 
concentration of 1x10
5
 cells/ml. Into a eppendorf with 100µl of the solution 5µl of FITC 
annexin V and 5µl PI was added then incubated in the dark at room temperature for 10-15 
minutes to allow binding. After this period 400µl 1X binding buffer was added to each tube 
and analysis using BD FACScalibur Flow Cytometer was done within 1 hour.   
2.3.3. Total Ribonucleic Acid (RNA) extraction 
Total RNA was extracted from both treated and untreated cell lines (HeLa, ME180 and 
KMST-6) using High Pure RNA Isolation Kit (Roche, German-RSA). Cultured cell were 
trypsinized, pelleted and resuspended in 200μl PBS. Cells were then lysed in 400μl of lysis-
binding buffer and then vortexed for 15seconds. The sample was then transferred into the 
High Pure Filter tube, incubated for 1 minute and then centrifuged for 15 seconds at 8000X g 
at room temperature. The flow-through liquid was discarded to leave behind the sample 
attached into the High Pure Tube. Samples remaining in the High Pure Tube membrane and 
in the collection tube were incubated with a mixture of incubation buffer and DNAase I for 
15 minutes at room temperature. The High Pure Tube together with collection tube was 
further washed with 500μl of wash buffer I and centrifuged for 15 seconds at 8000X g. The 
flow-through was discarded and the tubes reassembled and the washing was repeated with 
500μl wash buffer II. A third wash was done with 200μl Wash Buffer II at 12 000X g for 2 
minutes at room temperature. The High Pure Tube was transferred into a sterile 1.5 ml micro 
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centrifuge/ eppendorf tube. Then 50μl of RNA Elution Buffer was added to the assembled 
micro centrifuge tube and High Pure Tube to elude the total RNA and incubated for 1 minute. 
The elution was carried out by centrifuging at 12 000X g for 2 minutes.  
The total RNA was quantified using a Nanodrop (NanoDrop technologies, USA) at 260 and 
280nm as per manufactures guide. The quality of 260/280 ratio more than 2.0 was regarded 
as pure and this was further accessed with RNA electrophoresis (Appendix B17). Remaining 
RNA was aliquoted into 10μl of aliquots and stored at – 80 ºC for future use.  
 
2.3.4. RNA electrophoresis 
Once, RNA had been extracted, 1% (w/v) agarose gel (dissolved in 10ml 10X 3-(N-
morpholino) propanesulfonic acid buffer, MOPS and 72 ml sterile water) was made and 
allowed to cool to about 50ºC, 18ml of 37% (v/v) formaldehyde was added and mixture was 
stained with 3 µl of 100 µg/ml ethidium bromide (EtBr). Ten microlitres of total extracted 
RNA together with 10 µl of freshly prepared formaldehyde gel loading buffer will be mixed 
and heated at 65ºC for 5 min allowed to cool on ice for 2 minutes and the loaded on the gel 
which will be ran at 100Volts for ± 2 hours in 1X MOPS (Appendix B3). 
 
2.3.5. Total Deoxyribonucleic Acid (DNA) extraction  
Fragments of DNA released from the untreated and treated cells during necrosis or cell-
mediated cytotoxicity, or within the cytoplasm of apoptotic cells can be analyzed by 
extracting DNA. A Quick-gDNA™ MiniPrep kit, from Zymo Research was used to extract 
DNA from untreated and treated cells (HeLa, ME-180 and KMST-6). Cells were harvested 
into sterile 15 ml tube and washed with 1X PBS centrifuged for 10 minutes at 10° C (1200 
rpm). The supernatant was discarded and the cell pellet was resuspended in 1X PBS. Cells 
pellet was washed twice with 10 ml 1X PBS and centrifuged between the washes. The pellet 
was resuspend in 200µl Genomic Lysis buffer, vortexed and allowed to stand for 5- 
10minutes at room temperature. The mixture was transferred to Zymo- Spin™ Column in a 
collection tube. This was centrifuged at 10 000X g for 1 minute and the collection tube with 
the flow through was discarded. The Zymo-Spin™ Column was transferred into a new 
Collection Tube then 200 µl of DNA Pre-Wash Buffer was added to the spin column, 
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centrifuging the column at 10,000 x g for 1 minute. 500 µl of g-DNA Wash Buffer to the spin 
column was added and further centrifugation at 10,000 x g for one minute. The spin column 
was transferred to a clean microcentrifuge tube and ≥50 µl DNA Elution Buffer was added to 
the spin column.  This was incubated for 2-5 minutes at room temperature and then centrifuge 
at top speed for 30 seconds to elute the DNA. The eluted DNA was used immediately to 
investigate whether DNA had been fragmented after treating cells with 150µg/mL T. violacea 
and A. palmeri for 24 hours or stored ≤-20ºC for future use. DNA concentration was 
measured using a nanodrop (NanoDrop technologies, USA) as per manufactures guide. 5 µl 
of each DNA sample was run on 1% agarose gel electrophoresis.  
Gel electrophoresis is used as a visualisation technique, to investigate on whether treated and 
untreated cells have DNA fragments, smears or one band when undergoing apoptosis, 
necrosis or cell proliferation, respectively. 
 
2.3.6. Agarose gel electrophoresis of DNA 
The principle of agarose gel electrophoresis involves separation of nucleic acids according to 
their size and conformation. During this technique the DNA fragments can be visualized by 
staining the gel with ethidium bromide, that intercalates between bases of DNA and 
illuminating the gel under UV light on a transluminator. Nuclear changes such fragmentation 
of DNA occur during apoptosis. Agarose gel electrophoresis is a technique used for 
separation of nucleic acids according to size and charge. The DNA fragments were then 
visualized by staining the gel with ethidium bromide at a concentration of 1μg/ml, which 
intercalates between bases of DNA and illuminating the gel under UV light using a 
transluminator. Agarose gel (1%) (Appendix B2) was prepared in 1 X TBE and contained 2μl 
ethidium bromide in order to electrophorese the DNA samples. The DNA molecular weight 
marker used was from Fermentas Mass Ruler DNA ladder mix, Ready-to-use, 80-10 000bp 
(Appendix B, Figure 1.19). Gels were then subjected to 70 volts for 90 minutes in 1X TBE 
buffer. 
2.3.7. Reverse transcription (RT) 
Promega‟s cDNA synthesis kit for RT-PCR (Promega, USA) was used to synthesize cDNA 
for gene expression studies. The enzyme, reverse transcriptase, in the kit synthesizes a new 
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cDNA strand at the site determined by the type of primer used and the resulting cDNA is then 
used as a DNA template for normal PCR. 
Reserve transcription was therefore performed as per manufacturer instructions as follows: A 
total RNA sample of 2μg was mixed with 0.5μg per reaction oligo (dT)15 primer and 
incubated at 70 ºC for five minutes to denature any secondary structures and to allow the 
primers to anneal. The template preparation was then placed in ice for 5 minutes. The 
preparation (Appendix B) was then mixed with the rest of the components of the cDNA 
synthesis reaction tabulated in table 1.2 (Appendix B). The samples were mixed and briefly 
centrifuged. Following this samples were incubated at 25 ºC for 10 minutes to allow the 
primers to anneal at their sites. This was followed by incubation of samples at 42 ºC for 60 
minutes to allow reverse transcription. Reverse transcriptase was inactivated by incubation at 
70 ºC for 10 minutes and the sample were cooled on ice. The sample were either used 
immediately for qRT-PCR or PCR or stored at -20 ºC for later use. 
 
2.3.8. Polymerase Chain Reaction 
2.3.8.1. Primers 
To amplify a fragment of the translated regions and to measure the expression of TP53, 
Retinoblastoma Binding Protein 6 (RBBP6) and RB1 genes, the following primers were 
designed using the National Centre for Biotechnology Information (NCBI) website and once 
the primer sequences were identified, the sequence was sent to Inqaba Biotechnological 
Industry, (SA) for synthesis.  
p53 primers: 
Forward primer: 5´ GGC CCA CTT CAC CGT ACTA A 3´ 
Reverse primer: 5´ GTG GTT TCA AGG CCA GAT GT 3´ 
 
RBBP6 primers:    
Forward primer: 5´ CAG CGA CGA CTA AAA GAA GAG TCT 3´ 
Reverse primer:  5´ GGT AAT TGC GGC TCT TGC CT 3´ 
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Rb1 Primers:  
Forward primer: 5´ TGC ATG GCT CTC AGA TTC AC 3´ 
Reverse primer: 5´ AAG GCT GAG GTT GCT TGT GT 3´ 
Polymerase chain reaction (PCR) is a technique that allows logarithmic amplification of short 
DNA sequences of between 100 to 600 bases pair within a longer double stranded DNA 
molecule. Primers for genes of interest were designed using Nucleotide sequences from 
NCBI. The cDNA obtained through reverse transcription was used as a DNA template. The 
PCR was performed using a master mix from Promega (USA). The master mix contains 
deoxyribonucleotides, 2X PCR buffer, MgCl2 and Taq Polymerase. A total of 25μl reactions 
required exactly 12.5μl master mix; 1μl (10pmoles) of each of the sequence specific primers; 
2μl 25mM MgCl2; 1μl template DNA (1pg-1μg) and 7.5μl nuclease-free water (Appendix 
B). The reactions were then subjected to approximately 30-35 cycles of the three PCR steps 
(denaturation, annealing and extension) after the initial denaturation step and followed by a 
final extension step. The steps were as follow with some variation in annealing temperature 
and extension time depending on the nucleotide sequence of the gene of interest: 
95 ºC for 2 Min 
94 ºC for 30 sec 
Tm-5 for 30 sec                    30-35 cycles 
72 ºC for 30 sec 
72 ºC for 10 Min 
 
The products were stored at 4 ºC until further use for RT-PCR. 
2.3.9. Quantification of mRNA using RT-PCR 
Real time polymerase chain reaction is the most sensitive technique for simultaneous mRNA 
detection and quantification. It is used to quantitate changes in gene expression patterns. It 
can also be used to quantify mRNA levels from much smaller samples, such as mRNA from 
a single cell.  
 26 
 
To monitor cDNA amplification in RT-PCR, SYBR Green JumpStart Taq Ready Mix 
(Sigma) was used in our study. The mixture contains a JumpStart Taq DNA polymerase and 
only requires addition of template, primers and water. It is a fluorescent intercalating dye 
which presents the simplest and cheapest way of detecting PCR product in real time. The dye 
will only fluoresce when bound to double stranded DNA, thus allowing for fluorescence to 
increase as the number of double stranded DNA increases, this allows for DNA concentration 
to be quantified at each cycle. The real-time PCR cocktail together with the parameters are 
explained in Appendix B. Quantitative analysis of the mRNA transcripts was carried out. The 
real-time PCR cocktail together with the parameters taken into account were analyzed on the 
Roche LightCycler machine used for quantitative analysis of mRNA transcript explained in 
Appendix B in duplicate. The melting point was analysed using a RT-PCR to confirm the 
success of our amplification and it was indicated by a single peak at a melting temperature 
point of the product. 
2.3.10. Western blot/ Immunoblotting 
Western blotting, also referred to as immunoblotting, is well established and widely used 
technique for the detection and analysis of proteins. It is based on building an antibody 
protein complex via specific binding of an antibody to proteins immobilized on a membrane 
(such as nitrocellulose or polyvinylidene fluoride (PVDF) and detecting the bound antibody 
by various methods based on chemiluminescence, chemiflourescence, fluorescence, 
chromogenic or radioisotopic detection (Towbin et al, 1979). A workflow is giving below: 
 
 
2.3.10.1. Protein extraction 
Protein was extracted from cultured cells in monolayer using the Thermo Scientific RIPA 
buffer. This buffer allows protein extraction of cytoplasmic, membrane and nuclear protein. 
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Cells treated and untreated with plant extracts and staurosporine were washed with ice-cold 
phosphate buffer saline (PBS) twice, suspended in 500µl cold RIPA extraction buffer 
(Thermo Scientific, Rockford, USA) and kept in ice for 5 minutes, swirling the plate 
occasionally for uniform spreading. Using a cell scraper, a lysate was gathered and 
transferred into a 1ml eppendorf tube and centrifuged at ~14 000x g for 15 minutes to pellet 
the cell debris. The supernatant was transferred into a new eppendorf and stored at 70
o
C for 
further analysis.  
2.3.10.2. Protein estimation assay 
Protein estimation for calorimetric detection and quantification of total protein was done 
using the Pierce® Bicinchoninic (BCA) protein Assay Kit (Thermo Scientific, Rockford, 
USA). Protein concentration was determined and reported with reference to standards of 
bovine serum albumin (BSA). A series of diluted standards of BSA were prepared, where 
one ampule of BSA was serially diluted with distilled water into 1.5ml eppendorf tube in a 
working range of 20- 2000µg/ml in a volume of 3 replicates. Concurrently a serial dilution of 
the unknown sample of protein extracted from HeLa, ME-180 and KMST-6 cell line both 
treated and untreated with plant extract and staurosporine was prepared for measurement. 
Into a microplate well, 25µl of the solution from each test tube (standard and unknown 
sample replicate) was pipetted. 200µl working reagent (WR) containing a 50:1, BCA reagent 
A: B was added to each well and mixed thoroughly on a plate shaker for 30 seconds, then 
covered and incubated at 37
o
C for 30 minutes. The plate was cooled to room temperature the 
absorbance at or near 560nm was read using a plate reader.  The absorbance of the standards 
versus their concentration was plotted and the extinction coefficient was computed and the 
unknown protein sample concentration was calculated.  
2.3.10.3 Antibodies 
RBBP6, p53, Mdm2, Rb, Bax, Bcl 2 and β-actin mouse monoclonal primary antibodies (IgG) 
and goat anti mouse coupled with horseradish peroxidase (HRP) secondary antibody from 
SantaCruz Biotechechnology were used in the immunoblot experiments.  
2.3.10.4 Immunoblot analysis 
After the proteins were quantified, approximately 30-40µg of total cellular protein were 
boiled in 2X sodium dodecyl sulphate (SDS) sample loading buffer [(125mM Tris HCL, 4% 
(w/v) sds, 20% glycerol, 10% (V/V) 2- mercaptoethanol, pH 6.8)].The proteins were 
 28 
 
resolved in 12% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
(Appendix B) according to Laemmli (1970) at a constant voltage of 90 V with SDS-PAGE 
1X running buffer (Appendix B). One gel was stained with Coomassie Brilliant Blue R250 
after electrophoresis to check the transfer efficiency (Appendix B). Another gel with protein 
samples was then electro-blotted onto polyvinylidene fluoride transfer (PVDF) membrane 
0.45µm (Pall Corporation, Pensacola, FL, USA) using the Biorad mini trans-blot system at 
400milliamperes (mA) for 60 minutes at 4
o
C in a western blot transfer buffer (Appendix B). 
Upon completion of the protein transfer, the membrane was blocked with 0.05% fat free milk 
(Appendix B) for 1 hour shaking slowly at room temperature in order to block non-specific 
binding sites After blocking, the membrane was incubated in blocking buffer containing a 
specific primary mouse monoclonal antibodies: p53 (1:750), P2P-R (1:500), Rb (1:2500, 
Mdm2 (1:250), Bax (1:750), Bcl-2 (1:500) and β- Actin (1:1000) at 4oC overnight. 1: 2000 
primary antibody of interest and incubated overnight at 4
O
C in the shaker. β actin was 
utilized as an internal control. To remove residual antibody, the membrane was washed with 
0.1%PBS+ Tween 20 3 times at 10 minute intervals. Then the membrane was ready for 
incubation with goat anti-mouse (IgG) HRP conjugated secondary antibody at 1: 10 000 in 
blocking buffer for 2 hours at room temperature. The membrane was then washed with 1X 
PBS + 0.1 % Tween as described above. The membrane was then exposed to Thermo 
Scientific SuperSignal West Dura Substrate, a luminol-based enhanced chemiluminescence 
(ECL) HRP substrate (Thermo Scientific, Rockford, USA) for 10minutes in order to detect 
immunoreactive proteins. These were then visualized using a ChemiDoc XRS Image 
Analyzer (Biorad Laboratories, Inc., USA). Each immunoblot was repeated 3 times. 
 
2.3.11. Statistical analysis  
The results of each series of experiments (performed in triplicates) were expressed as the 
mean values ± standard deviation of the mean (SD). Levels of the statistical significance 
were calculated using the paired t-test when comparing two groups (Graph Pad Instat 
program found on http://www.graphpad.com/scientific-software/instat/) and the P-values, 
P<0.05 were considered significant. 
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CHAPTER 3 
RESULTS  
3.1. Introduction 
The purpose of this study was to screen Tulbaghia violacea and Agave palmeri plant extract 
for RBBP-6 anti- cancer therapy in cervical cancer. However, with little knowledge on these 
two plant extracts‟ mode of action and their chemical profiles together with active 
compounds, we had to first identify one suitable solvent to extract active compounds that 
might be of importance in activating cell death in cancer cells.. The results obtained in this 
chapter address the following hypothesis: 
I) Plants extracts of Tulbaghia violacea and Agave palmeri have anti-proliferative properties 
and induce cell death in cervical cancer cell line (HeLa and ME180). 
To prove this hypothesis a variety of experimental procedures were carried out; these 
involved MTT assay (cell cytotoxicity/ viability assay), Flow Cytometry (Annexin V)/ 
apoptosis detection, and immunoblotting for the detection of apoptotic protein expression.  
 
3.2. Tulbaghai violacea and Agave palmeri crude plant extracts have a cytotoxic effect on 
cervical cancer cells 
To examine whether Tulbaghia violacea and Agave palmeri extracts affects the viability of 
HeLa, ME-180, and KMST-6 (non-tumourogenic human embryo fibroblast) cell lines, the 
cells were treated with plant extract at 50-150 µg/mL for a period 8- 24 hours. As shown in 
figure 1.4 (A-D) and in figure 1.5 (A-B), cell viability was slightly decreased following 
treatment by T. violecea and A. palmeri in a dose-dependent manner over 24 hours. 
Sensitivity at the highest concentration tested (150 µg/ml) was high in the following order: 
HeLa (figure 1.4 A and B), ME-180 (figure C and D) and KMST-6 (Figure 1.5 A and B) to 
crude plant extract of T. violecea and A. palmeri. The ever green leaves of T. violacea 
extracts in this study, have shown to have more anti-proliferative effect in HeLa cells at a 
concentration dependent cytotoxic activity with half maximal inhibitory concentration (IC50) 
value greater than 150µg/ml exhibiting 58% cell viability and 42% cell death following 24 
hour treatment (Figure 1.4A). However, in ME-180 and KMST-6 at the same concentration it 
exhibit a weak cytotoxicity activity with both  21% and 18% cell death respectively after 
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treatment (figure 1.4C and 1.5A). 
 
On the other hand, after treatment with A. palmeri, results obtained suggested that crude 
extracts did not exhibit our expected anti-proliferative activity in both ME-180 (figure 1.4 D) 
and KMST-6 (figure 1.5B) cell lines, but showed very little cytotoxic activity on HeLa cell 
line (figure 1.4B) at >150µg/ml which was our maximum concentration in which only 34% 
cell death was induced. However, following treatment at 100µg/mL for 24 hours only 32% 
cell death was induced in HeLa cell (figure 1.4 B). In summary, the crude plant extract of T. 
violecea and A. palmeri highly reduced cell viability in HeLa but not in ME-180 and KMST-
6 cell line at the concentration of 150µg/ml as compared to control experiments **p<0.10.  
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ST was shown to inhibit cell viability at a concentration of 25nM in HeLa, ME-180 and 
KMST-6 (figure 1.4 and 1.5) cell lines after 24-hour treatment. Consequently, to determine 
whether the inhibition of cell viability by these plants extract (TV and AG) and ST resulted 
from apoptosis, a measurement of the cell population after 24-hour treatment was done by 
flow cytometry. 
 
3.3. Tulbaghia violacea and Agave palmeri crude plant extracts trigger DNA 
fragmentation in HeLa and ME-180 cervical cancer cell line  
To gain an insight on the effect of crude plant extract of T. violacea and A. palmeri on the 
nuclear alteration, the hallmark of apoptosis, DNA fragmentation. The effect of these were 
analysed on HeLa, ME-180 and KMST-6 cell lines. To detect these two changes, cells were 
treated with 150µg/ml of T. violacea and A. palmeri together with 25nM of staurosporine for 
24 hours.  
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Figure 1.6 shows that the occurrence of DNA fragmentation is indicated by the distinct smear 
of nuclear material which is indicative of DNA fragmentation on the wells of the gel. 
Normally, this is represented by distinct multiple bands on the agarose gel. From our results 
with untreated cells as represented in lanes 2, 6 and 10 there seem to be no apoptosis that was 
initiated as the is still one distinct single band as compare to other lanes that have shown a 
smear or DNA fragment especial from those cells treated with ST (figure 1.6).  
 
 
3.4. Tulbaghia violacea and Agave palmeri crude plant extracts trigger apoptosis in 
HeLa and ME-180 cervical cancer cell line 
Advances in DNA fragmentation are preceded by the alteration in PS where during the early 
stages of apoptosis, the PS asymmetry is lost because of its externalization (Wong and Kadir, 
2011). This particular feature change was investigated using the Annexin V/PI staining kit, 
where cells treated and untreated with plant extract were double stained with Annexin V-
FITC/PI or unstained and analyzed by flow cytometry (figure 1.7, 1.8 and 1.9), described in 
chapter 2, section 2.3.2. It was vital to include negative and positive controls in this 
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experiment, in order to make sure that the selected population to be analyzed was a true 
reflection of the events that were taking place after treatment with plant extracts and that cell 
debris was eliminated from the calculation of cells undergoing apoptosis as well as 
eliminating those that are alive or necrotic. The graphs below are representative of the flow 
cytometry apoptosis analysis. 
 
According to figure 1.7 (A) and 1.7 (B) untreated KMST-6 cells, which were not stained with 
Annexin V/PI showed low or negative staining for both AnnexinV/FITC and PI (AnnexinV-
FITC/PI), indicating live cells (96.4% live). The untreated stained (AnnexinV-FITC/PI) had 
low staining for both AnnexinV/FITC and PI indicating more viable cells (88.3% live). After 
treatment with 25nM ST, 150µg/ml TV or AG for 24 hours, the cells started to undergo 
apoptosis, shown in figure 1.7 (C), 1.7 (D), and 1.7 (E) respectively. Early (Annexin V +/PI-) 
and late (Annexin V +/PI +) apoptotic cells represented was approximately 13.4% of KMST-
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6 cells at early apoptosis, 24.0% at late apoptosis and 8.4% undergoing necrosis after 
treatment with staurosporine (ST). After treatment with TV 4.4% of the cells underwent early 
apoptosis, 3.9% were at late apoptosis and 1.9% at a necrotic stage whereas treated with AG 
induced early apoptosis (1.2%), late apoptosis (2.0%) and necrosis (1.8%) in KMST-6 cell 
line.     
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As shown in figure 1.8 (A), 1.8 (B) and 1.9 (A), 1.9 (B), before HeLa and ME-180 cells were 
treated, 93.3% and 96.0% respectively of the cells were viable, with mostly negative staining 
for both AnnexinV/FITC and PI respectively. When HeLa cells were treated with ST, most of 
the cell population underwent cell death (83%), with a small percentage of cells (3.1%) in 
early apoptosis and late (8.8%) apoptosis.  When these cells (figure 1.8) were exposed to TV 
and AG they showed a similar pattern to those that were treated with ST. Most of the 
population were undergoing cell death that resembled that of a necrotic cell, with TV treated 
cells showing 56.2% necrosis, 6.9% early apoptosis, 34.2% late apoptosis and AG treated 
cells at 72.7% necrotic, 8.0% early apoptosis, 14.3% late apoptosis stage (figure 1.8 (D), 
1.8(E). It is important to note that, at every treatment dose and exposure time of HeLa cell 
lines, the necrotic cell population was higher. This indicates that necrosis was the preferential 
form of cell death induced by plant extract TV, AG in HeLa cell lines. This is in contrast to 
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effects on the ME-180 cell line, as shown in figure 1.9 (C), 1.9 (E), and 1.9 (F), where the 
cell population after treatment at dose and exposure time had greater amounts of cells 
undergoing apoptosis. When cells were treated with the positive control (ST), 13.4% of the 
cell population underwent early apoptosis, 80.7% late apoptosis, 2.0% necrosis and 3.9% of 
them were living (figure 1.9 C). After TV and AG plant extract treatment, 15.1% of the cells 
were in early apoptosis, 27.1% in late apoptosis, 15.1% necrosis, 42.7% live and 30.2% early 
apoptosis, 39.8% late apoptosis, 3.2% necrosis, 26.9% live respectively (figure 1.9 (D), 1.9 
(E). This suggests that externalized phosphatidylserine residues were present and that 
apoptosis was a preferred form of cell death with the necrotic population as small as, between 
2.0%- 15.1% after treatment.  
Apoptosis is controlled by a numerous number of cascades of events closely monitored by a 
number of genes. These involve a network of genes and their products, which play a vital role 
in this process. In most cancers p53 function is impaired and its role as a tumour suppressor 
gene is lost, whereas RBBP and other similar genes such as Mdm2 which are highly 
expressed with an ability to interact with p53 together with other genes such as Rb 
perpetuating cancer development. The balance in the Bcl-2 family of proteins such as the Bax 
and Bcl-2 ratio is also important. In this study, flow cytometry analysis was followed by an 
analysis of the expression levels of proteins Bax, Bcl-2, p53, Rb, RBBP6 and Mdm2 which 
partake a role in apoptosis at a molecular level, using immunoblotting or Western blot 
analysis.  
3.5. The effects of Tulbaghia violacea and Agave palmeri crude plant extracts on Bax, 
Bcl-2, p53, Rb, RBBP6 and Mdm2 protein 
In this study, the effects of T. violacea and A. palmeri extract effect on Bax, Bcl-2, p53, Rb, 
RBBP6 and Mdm2 protein expression profiles of HeLa and ME-180 tumourigenic cell lines 
after exposure to 150µg/ml for 24 hours were assessed by Western blotting. Members of the 
tumour suppressor proteins (p53 and Rb) together with the Bcl-2 family of proteins such as 
Bax, Bcl-2 and other nuclear proteins such RBBP6 and Mdm2 are well known in playing a 
crucial role promotion or inhibition of apoptosis and cell proliferation. Exposure of HeLa and 
ME-180 cell lines to plant extracts (TV and AG) may either result into up-regulation or 
down-regulation of various proteins which either plays a crucial role in induction or 
suppression of apoptosis or in the inhibition cell proliferation. β- Actin was utilized to 
normalize protein loading during western blotting.   
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The results (Figure 1.10) demonstrates that the expression level of Bax was well expressed in 
ME-180 and HeLa cell lines treated and untreated with T. violacea, A. palmeri and in positive 
control staurosporine. The Western blot also demonstrates that the expression level of Bcl-2 
is differentially expressed in ME-180 and HeLa cell lines treated and untreated with T. 
violacea, A. palmeri and a positive control staurosporine.   
 
Figure 1.10 I, II, II represent HeLa and ME-180 cells treated with plant extracts and probed 
with β- Actin, Bax and Bcl-2 antibodies following treatment with TV (Figure 1.10 I, II, III C 
& G), AG (Figure 1.10 I, II, III D & H) and ST (Figure 1.10 I, II, III B & F) respectively. The 
results indicate there was no notable effect on Bax protein expression in all the treatments 
whereas with Bcl-2 protein as indicated in figures 1.10 III showing a reduction in protein 
expression following treatment with TV and AG in both ME- 180 (C&D) and HeLa (G&H).  
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To further predict the mechanism of how T. violacea (TV) and A. palmeri (AG) induce 
apoptosis, western blots were performed to determine expression of p53, Rb, RBBP6 and 
Mdm2. When compared to controls (Figure 1.11 IIIA & E), the expression of p53 was higher 
in ME-180 and HeLa cells after treatment with ST (Figure 1.11 III B & F), TV (Figure 1.11 
III C & G) and AG (Figure1.11 III D & H). Thus, TV, AG and ST treatment increased the 
expression of p53, which highly favors apoptosis as a tumour suppressor protein. When ME-
180 and HeLa cell lines were treated with plant extract and staurosporine, the retinoblastoma 
(pRb) protein was upregulated in HeLa cells by the two plant extract as compared to ME-180 
(Figure 1.11 IV B, C, E). When the expression of the cell proliferating protein RBBP6 was 
analyzed by western blotting, we observed high levels of this protein in untreated ME-180 
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and HeLa cell lines (Figure 1.11 II A, B, E & F) as compared to treated cell lines. A 
phosphorylation event resulting into two splice variants (indicated by 2 bands) of RBBP6 was 
seen in figure 1.11 II (E) and (F) in HeLa cell lines that were untreated and treated with ST 
respectively.  RBBP6 was down regulated following treatment with TV and AG in both ME-
180 and HeLa cell line (Figure 1.11 II C, D, and 1.11 II G, F). When we looked at Mdm2 in 
ME-180 and HeLa cells following treatment with TV there was a decrease in the expression 
of Mdm2 protein (Figure 1.11 I C& G). When ME-180 cells were treated with AG the 
expression of Mdm2 was similar to the expression seen in untreated cells and ST ME-180 
cell lines. In untreated and ST treated  HeLa cell lines Mdm2 was slightly up regulated but 
down regulated in TV and AG treated cells (Figure 1.11 I E, F, G and H).  
3.6. The effects of Tulbaghia violacea and Agave palmeri crude plant extracts on p53 and 
RBBP6 mRNA expression 
In order to confirm our earlier results on the expression levels of RBBp6 and p53 proteins, 
we conducted qRT-PCR to confirm the results obtained in our western blot analysis. Our 
results indicate that when RBBP6 mRNA increases p53 decreases as indicated in figure 1.17 
following treatment with both AG (A) and TV (B) respectively.   
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CHAPTER 4 
DISCUSSION 
 
Agents, which are mostly derived from plants and have potential ability to suppress cell 
proliferation at the same time enhancing apoptosis, have attracted a vast interest as anti-
cancer agents. Because many current available anticancer agents have side effects and even 
affect normal cells, traditional plants and their compounds have been screened for anticancer 
activities because in many studies they have been discovered to be safer (less toxic), easily 
available and cheaper when compared to modern (allopathic) drugs hence many people 
especially in the developing countries such as Southern Africa still rely on them to treat 
various ailments (Agarwal et al, 2012). Anticancer drugs like those derived from C. roseus 
(Vinblastine) have fuelled the search for more safe affective plant derived compounds that 
can be potentially utilized as anticancer agents (Fabricant and Fransworth, 2001).  
 
It is important to understand the molecular and signaling pathways that are activated by 
traditional plants such as Kedrosis foetidissima, which was reported to possess anti-
proliferative effects and also to induce apoptosis in a p53 independent manner in MCF-7 and 
YMB-1 breast cancer cells in the study by Choene and Motadi, 2012. Thus, it is due to such 
discoveries that Tulbaghia violacea (TV) and Agave palmeri (AG) were evaluated for their 
anti-cancer activity on HeLa and ME-180 cervical cancer cell lines in this study. The first 
objective was to evaluate the significant variation in the cytotoxic effects of TV and AG on 
the HeLa and ME-180 tumourogenic cell lines by measuring cell viability using MTT assay. 
This assay measures the concentration at which 50% of the cells died after exposure to crude 
TV and AG plant extract after 24 hours. The half maximal inhibitory concentration (IC50) of 
150µg/mL T. violacea exhibited 58% cell viability/ 42% cell death in HeLa cells (Figure 
1.4A) and weak cytotoxicity activity on both ME-180 and KMST-6 cells at 21% and 18% 
cell death respectively after treatment (Figure 1.4C and 1.5A) treated for 24 hours.  
 
This investigation correlates with that carried out by (Bungu et al, 2006), where 250µg/ml 
methanolic T. violacea leaf and bulb extracts inhibited cell proliferation due to apoptosis 
induction in HeLa, MCF-7, and WHCO3 and HT29 cell lines. The 150µg/ml of TV leaf 
extract in this study reduced cell viability in the HeLa cell line, in comparison with 250µg/ml 
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TV leaf extract inhibiting growth of HeLa (37.5±2.7%) with p<0.001 for all cell lines (Bungu 
et al, 2006). Further studies on the same plant also showed induction of cell death in 
oesophageal cancer (Van Wyk and Gericke, 2000; Lyantagaye, 2011). This action is possibly 
attributed by the presence of compounds such as C-S lyase, S-substituted cysteine sulfoxide 
derivatives, 2,4,5,7-tetrathiaoctane-2,2-dioxide and 2,4,5,7- tetrathiaoctane which have been 
extracted from leaves of this plants and have been reported to inhibit cell proliferation 
(Jacobson et al, 1968; Burton and Kaye, 1992; Srivastava and Singh, 2004).  
 
Not much has been reported on A. palmeri species, but ethanol plant extracts from the same 
subfamily such as Agave lechuguilla together with crude/ crystallized saponin extracted from 
this plant have been reported to respectively have a cytotoxic effect on HeLa cell lines with 
IC50 of 89µg/ml and 78-95µg/ml, but had a higher IC50 value of 171.6 and 172.2µg/ml when 
normal control Vero cells were treated in vitro (Casillas et al, 2012). In other studies like that 
of Yokosuka et al, (2000) and another by (Barret, 2001), cytotoxic effect of hecogenin and 
tretragylcosides saponin extracted from A. americana against Leukemia cell line HL-60 have 
been reported. These reports suggest that A. palmeri which belongs to the same family as A. 
lechuguila and A. americana may be harboring compounds similar to those that were 
responsible for cytotoxic effect on HL-60 and HeLa cells, confirming the response observed 
in this study where A. palmeri was shown to slightly reduce cell viability in HeLa cells 
(approximately 34% cell death) but not in the ME-180 and KMST-6 normal fibroblast cell 
line where 15% cell death was observed after 24 hour treatment. We further suggest that, A. 
palmeri has little cytotoxic effect on HeLa, ME-180 tumourogenic cells but none in KMST-6 
cell lines.  
 
Staurosporine, a known inducer of apoptosis, is a potent inhibitor of a number of protein 
kinases and known to promote intracellular stress-induced apoptosis in cell culture (Benard et 
al, 2001; Feng and Kaplowitz, 2002). As a positive control, cells treated with staurosporine 
(ST) were included in this study together with untreated cells. From the results, it can be 
deduced that HeLa and ME-180 cells together with KMST-6 non-tumourogenic normal 
fibroblast cell lines consistently entered apoptosis after exposure to ST and there was no 
significance between T. violecea, A. palmeri and ST (P<0.10) treated HeLa, ME-180 and 
KMST-6 cell line shown in Chapter 3 (Figure 1.4 and 1.5) when looking at the cell cytotoxity 
which was between 34-58% induced by 25nM ST. These results are in line with those from 
Bernard et al, 2001, where they reported irreversibly induced apoptosis in HeLa, Caski (HPV 
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positive, wild-type p53) and C33A (HPV negative, mutated p53) after 24 hours treatment 
with ST at concentrations between 2-40nM. Because calorimetric assays, such as MTT used 
in this study can be disadvantageous in the sense that it may underestimate cellular damage 
and detect cell death at a later stage of apoptosis when metabolic activity of the cells is 
reduced, it was therefore pivotal to extract DNA of treated and untreated HeLa, ME-180 and 
KMST-6 cell lines which was analysed using gel electrophoresis. 
 
Initially apoptosis is characterized by numerous morphological and biochemical features, 
these include condensation and fragmentation of the nuclear chromatin, nuclear 
fragmentation compaction of the cytoplasmic organelles with cell shrinkage and loss of 
positional organization of organelles in the cytoplasm, dilation of the endoplasmic reticulum, 
a decrease in cell volume and alteration to the plasma membrane resulting in the recognition 
and phagocytosis of the apoptotic cells (Lee et al, 2009; Taraphdar et al, 2001; Wong and 
Kadir, 2011). The DNA fragmentation, results also confirmed that ST induces apoptosis in 
HeLa, ME-180 cervical and KMST-6 normal fibroblast cell lines at concentration 25nM after 
24 hour treatment when DNA was extracted and analyzed through gel electrophoresis (Figure 
1.6 lane 3, 7, 11). During apoptosis especially in the later stage, the endonucleases provoke 
degradation of nuclear DNA, which results in the fragments of DNA strand breaks (DSBs) 
which have exposed hydroxyl ends (Compton, 1992). Anti-cancer drug mechanism of action 
is based on the ability to induce apoptosis and in some cases inhibit apoptosis (Lee et al, 
2009).  
 
Based on the statement above, it was therefore vital that T. violacea and A. palmeri induce 
apoptosis in order to be considered potential anti-cancer plant extracts. From the results in 
figure 1.6 TV and AG were able to induce cell death as shown with a distinct smear 
indicative of a fragmented DNA. However in KMST-6 cells which are normal fibroblast cells 
the two plant extracts did not induce any form of cell death, which suggested that the plant 
extracts do not interfere normal cells (Figure 1.6). This pattern was similar to that obtained 
when MCF-7, WHCO3, HT29 and HeLa cell lines were treated with T. violacea bulb and leaf 
methanol extract, where fragments were seen as one of the hallmarks of apoptosis and 
nuclear condensation was observed after treatment (24 hours) and staining with Hoechst 
33342 with a number of cells significantly apoptotic and even more so after 48 hours of 
treatment (Bunge et al, 2006). This fragmentation pattern is a sign of growth inhibitory action 
associated with apoptosis induction induced by TV and AG plant extract.  
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Cells death is defined by a decrease in cell viability and DNA fragmentation in this study, is 
known to occur in 2 distinct modes: apoptosis, which starts with a blebbing of the plasma 
membrane, which breaks up into membrane-enclosed particles, called apoptotic bodies, 
containing intact organelles as well as portions of the nucleus and followed by a well-
choreographed sequence of morphological events characterized by features such as DNA 
fragmentation, a laddered size distribution to DNA cleavage between nucleosomes (Kerr et 
al, 1972; Kastan et al, 1995). Necrosis, a form of cell death shown by cytoplasmic swelling 
and vacuolation, rupture of the plasma membrane, dilation of organelles such as the 
mitochondria, endoplasmic recticulum and Golgi apparatus, as well as moderate chromatic 
condensation (Festjens et al, 2006).  
 
Therefore to characterize the mode of cell death associated with T. violacea and A. palmeri 
induced growth inhibitory activity in HeLa and ME-180 tumourogenic cell lines, the 
morphological changes associated with apoptosis were assessed using Annexin V/PI staining 
kit. During apoptosis, the distribution of neutral phospholipids and anionic phospholipids 
such as phosphatidylserine (PS) in the cell membrane changes (Rahman, 2005). Annexin V 
coupled to FITC is a dye that can be added to the cells and is specific for PS, and will bind to 
PS on the outer membrane of apoptotic cells whereas PI is an intercalating dye used to 
identify cells that are at a late stage of apoptosis in a population (Rahman, 2005). So when 
HeLa and ME-180 cells together with normal fibroblast KMST-6 cell lines were dual stained 
with AnnexinV/FITC and PI before and after treatment with TV, AG and ST (the positive 
control), apoptosis was induced. HeLa, ME-180 tumourogenic and KMST-6 cells treated 
with TV and AG at a concentration of 150μg/mL demonstrated phosphatidylserine residue 
externalization as indicated by percentage of cells in the population which were either at early 
or late stage of apoptosis. KMST-6 cell lines treatment with a known inducer of apoptosis 
ST, resulted in only 37.4% PS residue externalization whereas 8.3% when treated with TV 
and 3.2% with AG (Figure 1.8). On the other hand HeLa when treated with ST (83.3%), TV 
(41.1%), and AG (22.3%) and ME-180 treated showed ST (94.1%), TV (42.2%), and AG 
(70%) PS residue externalization.  
 
The rest of the cells were either alive or undergoing necrosis, as they stained negative for 
both AnnexinV-FITC/PI (live) and (-) AnnexinV/FITC (+) PI respectively. This 
demonstrated that treatment of HeLa; ME-180 and KMST-6 cells with staurosporine resulted 
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in significant induction of apoptosis. When KMST-6 normal fibroblasts were treated with TV 
and AG relatively no significant toxicity to the cells was observed with only 8.3% and 3.2% 
PS residue externalization suggesting normal proliferating cells could be protected from TV 
and AG plant extract. This correlates with the statement made by (Chen et al, 2000) about a 
good chemotherapeutic agent being able to induce apoptosis without being toxic to normal 
proliferating cells.  Notably, ST induced apoptosis in KMST-6 cells lines by 37.3%, 
suggesting that proliferation was inhibited in normal cells just as in a study by Chan et al, 
2000 where 0.5nM staurosporine treatment of normal breast epithelial cells inhibited growth 
by between 40-55% ad arresting cell cycle at a G0G1 phase. The mechanism of apoptotic 
induction by ST is poorly understood, but Zhang et al, 2004 suggest that the caspase-
dependent and independent apoptotic pathways play a crucial role in induction of apoptosis in 
melanoma cell lines. We deduce that the significant response of HeLa and ME-180 cells to 
ST is potentially attributed via caspase-dependent and independent apoptotic pathway.  
 
Potentially, TV and AG crude extracts contain anticancer agents. However, not much has 
been reported about the extracts of AG, whereas TV crude aqueous extracts have been shown 
to exhibit apoptosis inducing ability (Lyantagaye, 2011). Methyl-α-D-glucopyranoside 
(MDG) compound from T. violacea, which interferes with hexokinase bioactivities and 
reactive oxygen species have been reported to induce apoptotic death. In other studies, the 
flavonoids kaempferol, querocetin and myricetin found in TV reduced cell proliferation in 
vivo and reduced risk of pancreatic cancer by 23% (Pastorino et al, 2002; Lyantagaye, 2005; 
Ncube et al, 2011). The flavonoid, kaempferol, was reported to inhibit chemoaltract protein 
(MCP-1) in the study by Kowalski et al, 2005. Whereas, total phenolics, gallotanin, flavonoid 
and saponin content found in micropropagated plants of T. violacea had antifungal activity 
and their secondary metabolites can be used for medicinal purposes to treat cancer (Ncube et 
al, 2011). Thus, a number of compounds that are present in plants such as T. violacea and A. 
palmeri possibly interfere with numerous genes together with their protein products to exhibit 
apoptosis. Looking at the results, isolation of biologically active compounds from plant 
extract of TV and AG could yet provide an insight on the mode of apoptotic action. 
 
 
Apoptosis is known to occur through 2 signaling pathways: the extrinsic pathway mediated 
by TNF and the intrinsic pathway resulting into cytochrome c release (Fulda, 2009). 
Commitment of a cell to apoptosis by either of the pathways is dependent on the balance 
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between pro-apoptotic and anti-apoptotic protein (Fulda, 2010). In this study, the protein 
member of the Bcl-2 family, Bax and Bcl-2 were investigated. Bcl-2 is known to regulate 
permeability of Bax and the ratio of these two proteins is vital for apoptosis to occur (Kang 
and Reynolds, 2009). Bax is reported to translocate to the mitochondria where it is reported 
to antagonize the anti-apoptotic activity of Bcl-2 or form a channel that leads to 
mitochondrial release of cytochrome c (Hervouet et al, 2006 et al, 2007; Youle and Strasser, 
2008). In the cytosol, the presence of cytochrome c initiates the formation of apoptosome 
complex which will serve to recruit and activate initiator caspase -9 which in turn 
proteotically cleaves and activate caspase 3 thus inactivating various cellular proteins such as 
PARP (Letai, 2002; Kang and Reynolds, 2009). A potential cytotoxic drug therefore needs to 
be able to initiate a release of proteins such a cytochrome c from a mitochondrial space to 
allow it to combine to adaptor molecule such as apoptosis protease activating factor 1 (Apaf-
1), and also inactivate procaspase 9 within the apoptosome to turn on the cascade activation 
of caspase (3, 6, 7), resulting in morphological and biochemical changes associated with 
apoptosis (Kang and Reynolds, 2009). The ratio of anti-apoptotic and pro-apoptotic Bcl-2 
family members is their crucial rather than the expression level of one member of the family 
to regulate apoptosis sensitivity (Fulda, 2009). 
 
In many cancers there is a reported increase in the ratio of anti- to pro-apoptotic Bcl-2 
proteins. This imbalance confers cancer cells an apoptotic resistance and allows cells to 
continue proliferating (Fulda, 2009). Western blot analyses in this study revealed a down 
regulation of the Bcl-2 protein with an up-regulation and potentially an accumulation of Bax 
in cells treated with TV and AG (Figure 1.10 II and III). Increase in Bcl-2/Bax ratio promotes 
cell survival in this study as observed down-regulation of Bcl-2 will result in the ratio being 
reduced in this case favoring apoptosis. These results suggest that, TV and AG induced 
apoptosis. Agents targeting the Bcl-2 family of proteins have been reported to have chemo 
sensitizing effects when treatment was combined with conventional chemotherapeutic drugs 
in chronic lymphocytic leukemia (CLL) patients (Kang and Reynolds, 2009). An up-
regulation of Bax (Figure 1.10 II) implies a subsequent accumulation of Bax protein in the 
mitochondria therefore potential release of cytochrome c to activate caspase cascade. 
Therefore TV and AG modulate Bax and Bcl-2 expression levels at a protein level. In 
addition the balance of these proteins potentially activates caspase 9, 3, and possibly induces 
PARP cleavage in the cells.  
 
 46 
 
Other main mediators of apoptosis include a tumour suppressor protein p53; where an 
induction of p53 protein levels by various stress types such as (TV and AG crude plant 
extracts) may potentially prevent inappropriate propagation of cells carrying DNA damage, 
and mutation (Moll and Petrenko, 2003). Not only does p53 together with Rb gene products 
control apoptosis, they also play a role in cell cycle progression (Kastan et al, 1995). Most 
notably, p53 upregulation induces a transcription of cyclin dependent kinase (cdk) p21, and 
Mdm2 inhibiting Cdk2 activity, which controls a transition and arrest of G2/M phases in the 
cell cycle resulting in apoptosis (Kastan et al, 1995).  
 
Crude extracts of Tulbaghia violacea and Agave palmeri induce apoptosis in both HeLa and 
ME-180 tumorougenic cell lines. Western blot analysis indicated the mode of action of these 
axtracts and we deduce that the action is independent of p53. However, when both HeLa and 
ME-180 were treated with TV and AG they both had reduced the expression of RBBP6 but 
increased the level of p53 expression which was in line with several other studies that looked 
at the relationship between these two genes (Motadi et al 2011). Apoptosis is control by a 
vast number of genes and signaling molecules, thus TV and AG potentially control other 
genes and molecules within this apoptotic pathway in HeLa and ME-180 cell lines. T. 
violacea compounds have been extracted in other research and these compounds can be used 
to study the mode of action. On the other hand A. palmeri compounds have not been isolated 
but in other species like A. Americana compounds have been isolated, an isolation and 
identification of compounds in this plant can also aid in understanding the molecular 
mechanism of this plant that follows apoptosis induction observed in this study.   
 
4.1. Conclusion and Future Perspectives 
Recently several medicinal plants have been identified as having potential for the treatment 
of cancer. However the understanding of the molecular mechanism and signaling pathway 
that they elicit still remain a mystery. In this study the molecular mechanism of cell death 
induction by TV and AG on HeLa and ME-180 cell lines was determined. From the results 
we can suggest that the two extracts could be inducing cell death by interfering with the Bcl-
2/Bax ratio. Even though there was down regulation of RBBP6 after treatment with TV and 
AG there was little impact on the p53 level to suggest that cell death induced was due to 
increased p53 level. However, more work need to be done in order to further understand the 
mechanism of TV and AG in cancer cell apoptosis induction. 
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APPENDICES 
APPENDIX A: TISSUE CULTURE 
1. Growth Media 
 Eagle‟s minimum essential media (MEM with L-glutamine)/ Dulbecco's Modified 
Eagles Medium (DMEM)  
 10 % Fetal Bovine Serum (FBS) 
 1% Penicillin streptomycin (pen/strep) (Whitehead scientific (Pty) LTD) 
Make up to a total volume of 500ml and store at 4
o
C 
 
2. Phosphate buffer saline (1x) 
136.9 mM Sodium chloride 
2.68 mM Potassium chloride 
10.1 mM Disodium hydrogen phosphate dodecahydrate 
1.76 mM Potassium dihydrogen phosphate 
Adjust pH 7.2 to 7.3 
Make up to final volume with dH2O 
Sterilize for 20 min at 151 lbq 
Store at 4 °C 
 
3. Trypsin: Ethylenediaminetetra-acetic acid (EDTA) solution 
 Trypsin solution 
            0.01 % Trypsin 
      Make up to final volume with PBS 
 EDTA solution 
0.004 % EDTA 
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Make up to final volume with PBS 
MIX: 
50 % Trypsin solution 
50 % EDTA solution 
Store at 4 °C 
 
4. Freezing media 
5mL Dimethyl sulfoxide  (DMSO) 
35mL MEM/ DMEM 
10mL FBS 
Store at 4 °C 
 
5. MTT Assay 
MTT (3-(4, 5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), Sigma- Aldrich, Saint 
louis, Missouri, USA 
0.15g MTT   
30mL of 1X PBS 
To make 5mg/mL 
Mix well and filter through the 0.45µm and store at -20oC 
6. FITC Annexin V Apoptosis Detection Kit I 
BD Pharmingen™ Protocol: 
http://www.bdbiosciences.com/external_files/pm/doc/tds/cell_bio/live/web_enabled/6900KK
_559763.pdf 
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APPENDIX B: SOLUTIONS 
1. Electrophoresis 
10x TBE 
0.9M Tris base 
0.89M Boric Acid 
25mM EDTA, pH 8.3 
This stock solution was diluted 1X for the electrophoresis of agarose  
 
2. 1% Agarose gel 
1g Agarose (Sigma-Aldrich, Saint Louis, Missouri, USA) 
100mL 1X TBE 
Mix well and dissolve agarose by microwaving for a few minutes 
Cool and add 2µL ethidium bromide (EtBr) 
 
3. 10X MOPS 
0.4 MOPS, pH 7.0 
0.1M Sodium Acetate 
0.01M EDTA 
Make up to 1L with DEPC water 
0.1% DEPC (diethylpyrocarbonate) 
 
4. SDS-PAGE sample buffer (2X sample buffer) 
3.55ml Demonized water 
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1.25mL 0.5M Tris-HCl, pH 6.8 
2.5mL Glycerol 
2.0mL 10% (w/v) SDS 
0.2mL 0.5% (w/v) bromophenol blue 
Add 50µL of β-Mercaptoethanol to 950µl of sample buffer before use  
 
5. RIPA extraction buffer (Thermo Scientific, Rockford, USA) 
See suppliers manual online:  
http://www.piercenet.com/instructions/2161782.pdf 
6. Protein Estimation  
Pierce® BCA Protein Assay Kit, Thermo Scientific, Rockford, USA 
See: http://www.piercenet.com/instructions/2161296.pdf 
Example of standard curve (protein estimation) 
 
Figure 1.13: Showing an example of a protein estimation curve. The specific BSA standards, 
at varying concentration (20-2000µg/mL), x- axis and their respective absorbance value at 
560nm (y-axis) were used to calculate the unknown protein concentration in a given sample.  
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7. SDS-PAGE Running Buffer (10X) 
30.0g tris base 
144.0 Glycin 
10.0g SDS 
Dissolve in deionized water (dsH2O) and fill to 1000mL. Store 4
o
C  
 
8. Ammonium persulphate (APS) 
 A 10 % stock solution was prepared in deionised water  
This solution was stored at 4 oC or prepared fresh at all times 
 
9. Separating gel 
2mL 30% Acrylamide/ 1% Bis (Bio-Rad) 
1.25mL 0.5M Tris-HCl, pH 8.8 
50µL 10 % SDS 
50µL 10% Ammonium persulphate (APS) 
2µL 0.25 % N,N,N‟N‟-tetramethylenediamine (TEMED) 
1.65mL dsH2O 
10. Stacking gel 
0.5mL 30 % Acrylamide/ 1% Bis (Bio-rad) 
190µL 1.5M Tris-HCl, pH 6.8 
15µL 10% SDS 
15µL 105 Ammonium persulphate (APS) 
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1.05mL dsH2O 
1.5µL 0.25 % N,N,N‟N‟-tetramethylenediamine (TEMED) 
11. Coomassie Staining Solution  
0.25% Coomassie Brilliant Blue R 250 
45% Methanol  
5% Acetic acid 
12. De-staining solution 
12 % Glacial acetic acid 
10 % Methanol 
Make up to final volume with dH2O 
 
13. Western Blot 
10X SDS-PAGE Transfer Buffer (Western Blotting) 
25mM Tris-Base 
192mM Glycin 
20% Methanol 
pH 8.3 
Bring to 1L with deionized water 
Make 0.2M CAPS (Sigma-Aldrich, Saint Louis, Missouri, USA) 
88.52g CAPS in 2L deionised water  
 
14. 1X Transfer Buffer 
100mL 0.2M CAPS 
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200mL 10X transfer buffer 
200mL Methanol (MeOH) 
1500mL dsH2O 
Store at 4
o
C for further use 
 
15. Blocking Solution 
5 % non-fat milk powder 
Make up to final volume with 1X PBS or TBS + 0.01% Tween 20 
Store at 4 °C 
 
16. SuperSignal West Pico Chemiluminescent Substrate kit (Thermo scientific, 
Rockford, USA) 
Before use MIX: 
50 % Luminol/Enhancer solution 
50 % Stable peroxide buffer 
Store in the dark 
View membrane using ChemiDoc XRS image Analyse (Biorad laboratories Inc, USA) 
 
Table 1.1: RNA extraction protocol 
Step 1  Cells were harvested(10
6
) and re-suspended in 200 µl PBS  
Step 2 400 µl Lysis/Binding buffer was added, contents were mixed well, then added 
to upper reservoir of the High Pure Filter Tube assembly 
Step 3 These were centrifuged for 15seconds at 8000 x g, flow through was discarded. 
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Step 4 Each sample was incubated with a mixture of 90 μl DNase I Incubation Buffer 
and 10 μl DNase I for 15 minutes at 25°C. 
Step 5 Wash Buffer 1(500 μl) was added to each sample, these were centrifuged for 
15seconds at 8000 x g. Flowthrough was discarded. 
Step 6 Wash Buffer II (500 μl) was added to each sample, these were centrifuged for 
15seconds at 8000 x g. Flowthrough was discarded. 
Step 7 Wash Buffer II (200 μl) was added to each sample, these were centrifuged for 
2 minutes at 13000 x g. Flowthrough was discarded through collection tube. 
Step 8 50 μl of Elution Buffer was added then centrifuged for 1minute at 8000 x g 
 
 
Table 1.2: The cocktail for cDNA synthesis  
Reagent  Volume 
10X reaction buffer 2.0 µl 
25 mM Magnesium Chloride  3.0 µl 
Deoxyribonucleotide mix 2.0 µl 
Specific primers 2.5 µl 
RNase inhibitor 1.0 µl 
AMV reverse transcriptase 1.0 µl 
sdH2O 7.5 µl 
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RNA sample 1.0 µl 
Total volume 20 µl 
 
Table 1.3: Reverse transcription conditions 
Step Temperature Time (minutes) 
Step 1 25 °C 10  
Step 2  42 °C 60 
Step 3 70 °C 15 
Step 4 4 °C ∞ 
 
 
Table 1.4: Real-time PCR cocktail  
Reagent Volume 
SyBr Green 10 µl 
Forward primer 1 µl 
Reverse primer 1 µl 
H2O 7 µl 
1µl of the respective cDNAs were added lastly to the capillaries. 
Total 20 µl 
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Table 1.5: Real Time PCR parameters 
Analysis Cycle Segment Temperature in °C Hold time 
Enzyme 
activation 
1 1 95 2 minutes 
Quantification 35- 45 Amplification 
Denaturation 
Annealing 
Extension 
 
95 
57 
72 
 
45 seconds 
45 seconds 
45 seconds 
None 1 Final extension 72 10 minutes 
Melting  1 Melting curve 
Denaturation 
Annealing 
Extension 
 
95 
65 
95 
 
10 seconds 
15 seconds 
0.1°C/Sec 
None 1 Cooling 40 30 seconds 
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Figure 1.14: DNA Ladder, Mix from Fermentas, Thermo Fisher scientific, Rokford, USA, 
used in gel electrophoresis. 
 
Figure 1.15: Showing the PageRuler™ Prestained Protein Ladder Plus, from Fermentas, 
Thermo Fisher Scientific, Rockford, USA 
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17. Total RNA and complementary DNA (cDNA) Synthesis 
Total RNA isolated from KMST-6 human fibroblast and HeLa and ME180 cell lines was 
subjected to electrophoresis before it was used to synthesize cDNA by reverse transcription. 
The RNA was of good quality as demonstrated in figure 5.1 with distinct 18S and 28S rRNA 
bands as indicated the arrows. 
Figure 1.16: Gel electrophoresis indicating the integrity of the RNA extracted from the 
HeLa, ME-180 and KMST-6 cell lines, Lane-M represent the RNA molecular marker while 
lanes 1-3 represent HeLa, ME-180 and KMST-6 cell line RNAs respectively. The two bands 
indicated by the arrows as 28s and 18s, which is indicative of the great RNA integrity.  
28S 
18S 
 71 
 
18. Melt Curve and the standard curve for figure 1.12 C and D 
 
 
 
Figure 1.18: To access the efficiency of the primers, a standard curve was prepared based on 
serially dilution of HeLa cDNAs. The r value is equals to -1 
Figure 1.17: The above figure illustrates the Melting point with RBBP6 product at ~ 84 °C.  
